Immunosenescence and cancer predisposition in pediatric transplant recipients: An emerging paradigm.

Core Tip: Children who undergo organ transplantation often experience premature aging of the immune system, largely due to factors such as anti-thymocyte globulin exposure, cytomegalovirus reactivation, thymic dysfunction, and long-term immunosuppressive therapy. This accelerated immune decline substantially increases their risk of developing cancer both early and later in life. Adopting a biomarker-driven clinical approach, including senescence-related flow cytometry panels, T cell receptor excision circle/telomere assessments, and epigenetic aging markers, along with tailored immunosuppression strategies, vigilant cytomegalovirus management, and emerging therapies targeting senescent, thymic, or metabolic pathways may help lessen cancer risk and improve long-term patient outcomes.

INTRODUCTION

The paradox of pediatric immune aging

The phenomenon of Immunosenescence, progressive deterioration of immune function with advancing age, has traditionally been confined to geriatric medicine[ 1 ]. This paradigm is fundamentally challenged by accumulating evidence that pediatric patients undergoing solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT) experience accelerated immune aging, developing immunosenescent phenotypes within months to years that would typically require decades in healthy individuals[ 2 ]. This accelerated trajectory establishes pediatric transplant recipients as a unique population wherein chronological and biological immune age diverge dramatically, with profound implications for cancer predisposition, infection susceptibility, and long-term survival. Pediatric transplantation encompasses kidney, liver, heart, lung, intestinal, and hematopoietic stem cell grafts, collectively performed in thousands of children globally each year. While these interventions offer life-saving benefits, the requisite immunosuppressive regimens designed to prevent rejection inadvertently accelerate immune aging through multiple convergent mechanisms[ 3 ]. The delicate balance between preventing allograft rejection and preserving sufficient immune function for pathogen control and tumor surveillance is increasingly recognized as insufficient, as current approaches fail to account for the biological aging consequences of immunosuppression.

Defining immunosenescence in the transplantation context

Immunosenescence encompasses multiple hallmarks. Thymic involution with reduced naive T cell output, telomere shortening in lymphocyte populations, accumulation of terminally differentiated memory T cells, loss of T cell receptor (TCR) repertoire diversity, chronic low-grade inflammation termed “inflammaging”, and development of the senescence-associated secretory phenotype (SASP)[ 4 , 5 ]. In pediatric transplant recipients, these processes are dramatically accelerated through direct immunosuppressive effects, viral reactivation [particularly cytomegalovirus (CMV)], chronic alloantigen exposure, thymic injury from conditioning regimens or induction therapy, and sustained inflammatory signaling[ 6 ].

The clinical manifestation of accelerated immunosenescence is most evident in substantially elevated cancer incidence. Yanik et al [ 7 ] documented standardized incidence ratios (SIRs) for cancer in pediatric SOT recipients ranging from 19.1 (95% confidence interval: 17.3-21.1) for all cancers combined to 159-1280 by organ for post-transplant lymphoproliferative disease (PTLD), with excess risks extending beyond Epstein-Barr virus (EBV)-associated malignancies to encompass solid tumors including skin cancers, renal cell carcinoma, and thyroid cancer. These risk profiles mirror those observed in elderly populations with naturally occurring immunosenescence, suggesting fundamental alterations in immunosurveillance mechanisms despite the patients’ youth. To contextualize the wide range of reported relative risks across organs, ages, follow-up windows, and eras of immunosuppression/viral prophylaxis, we summarize representative epidemiologic cohorts in pediatric SOT and HSCT survivors in Table 1 [ 7 - 13 ].

Across studies, cancer risk estimates vary substantially by transplanted organ, age at transplant, time since transplant, and the underlying indication for transplantation. In pediatric SOT, registry linkage data show particularly pronounced heterogeneity for PTLD/non-Hodgkin lymphoma (NHL), with higher relative risks in intestine and thoracic (heart/Lung) recipients compared with kidney recipients, and a strong early post-transplant peak consistent with intense induction immunosuppression and primary EBV infection in EBV-naive children. Longer-term cohorts demonstrate that although early lymphoproliferative events dominate pediatric-onset cancers, solid tumor burden increases with extended follow-up into adolescence and young adulthood. In HSCT survivors, risk profiles differ again: PTLD tends to occur early, whereas therapy-related myeloid neoplasms and radiation-/graft- vs -host disease (GVHD)-associated solid tumors typically appear years later, underscoring the importance of era effects (conditioning intensity, T-cell depletion strategies, antiviral prophylaxis/monitoring practices) when interpreting pooled risk estimates[ 7 ].

Scope and objectives

This review critically examines the molecular and cellular mechanisms driving accelerated immune aging in pediatric transplant recipients, with particular emphasis on cancer predisposition pathways. We synthesize evidence across multiple transplant types, integrate emerging concepts including inflammaging and metabolic reprogramming, evaluate current biomarker strategies, and critically assess therapeutic interventions including senolytic agents, thymic regeneration approaches, and checkpoint inhibitor modulation. Our objective is to provide a comprehensive framework that positions accelerated immunosenescence as a central paradigm in pediatric transplant medicine, with immediate implications for clinical practice and future research directions.

MECHANISMS OF ACCELERATED IMMUNE AGING

Anti-thymocyte globulin-induced senescence

Mechanisms of anti-thymocyte globulin-mediated T cell depletion: Anti-thymocyte globulin (ATG) represents a cornerstone induction therapy in pediatric transplantation, yet its profound impact on immune aging trajectories has only recently been elucidated. ATG consists of polyclonal antibodies targeting multiple T-cell surface antigens, resulting in rapid and profound lymphocyte depletion through complement-mediated lysis, antibody-dependent cellular cytotoxicity, and induction of apoptosis[ 14 ]. Critically, ATG demonstrates selective depletion patterns, preferentially eliminating naive CD45RA+ CD28+ T cells while relatively sparing CD45RO+ memory populations[ 15 ]. Crepin et al [ 15 ] provided seminal evidence that ATG administration induces sustained immunosenescent alterations characterized by reduced CD4+ CD28+ T cells, increased CD4+ CD28 null populations, shortened telomeres, and elevated inflammatory cytokines persisting years post-transplant. The preferential naive T cell depletion fundamentally alters the immune landscape, accelerating the transition toward an aged immune profile characterized by memory T cell predominance, reduced TCR repertoire diversity, and diminished capacity for de novo antigen responses.

Long-term consequences of lymphocyte reconstitution: Post-ATG immune reconstitution occurs primarily through homeostatic peripheral expansion rather than thymic regeneration, particularly problematic in pediatric recipients, where thymic function may be additionally compromised by conditioning regimens or concurrent surgical thymic injury[ 16 ]. This expansion-driven reconstitution preferentially involves memory T cells undergoing oligoclonal proliferation, resulting in repertoire restriction and accelerated telomere attrition due to repeated division cycles[ 17 ].

Lee et al [ 18 ] demonstrated that ATG treatment results in expansion of CD28-negative T cell populations, a hallmark immunosenescence marker, while simultaneously reducing telomerase activity and activating cellular senescence pathways including p53 and p16INK4a. These findings suggest that ATG not only depletes existing T cell populations but also fundamentally alters regenerative capacity, creating conditions conducive to accelerated aging that persist throughout the post-transplant course.

CMV-mediated immune exhaustion

CMV as a major driver of immunosenescence: CMV reactivation represents a critical driver of accelerated immunosenescence in pediatric transplant recipients, with effects extending far beyond acute infectious complications. CMV seropositivity is associated with premature immune aging markers, including telomere shortening, increased inflammatory cytokine production, expansion of highly differentiated CD28- CD57+ T cell populations, and TCR repertoire restriction[ 19 ]. These associations, well-documented in elderly populations where CMV infection correlates with increased mortality and “immune risk profile”, manifest with accelerated kinetics in immunosuppressed transplant recipients[ 20 ].

Mechanisms of CMV-induced immune aging: The mechanisms through which CMV accelerates immune aging are multifaceted. Semmes et al [ 21 ] described how CMV infection drives clonal expansion of virus-specific T cells, leading to “memory inflation”, progressive accumulation of CMV-specific effector memory T cells that can occupy up to 50% of the CD8+ T cell compartment in some individuals. This massive clonal expansion occurs at the expense of naive T cells and other antigen specificities, progressively narrowing the TCR repertoire and reducing capacity for responses to novel antigens, including tumor-associated antigens.

Jackson et al [ 22 ] further elucidated CMV’s sophisticated immune evasion strategies contributing to persistent viral replication and chronic immune activation. These viral mechanisms include interference with major histocompatibility complex (MHC) class I antigen presentation through multiple viral proteins (US2, US3, US6, US11), inhibition of natural killer (NK) cell function via MHC class I homologs (UL18), modulation of cytokine responses, and induction of regulatory T cells. The cumulative effect is a state of chronic immune stimulation without effective viral clearance, promoting progressive shift toward terminally differentiated effector T cells (TEMRA) with reduced proliferative capacity, shortened telomeres, and functional exhaustion characteristic of aged immune systems[ 22 ].

CMV-specific interventions: The substantial contribution of CMV to accelerated immune aging suggests that aggressive CMV prevention and treatment strategies may mitigate immunosenescence. However, antiviral prophylaxis must be balanced against concerns that preventing CMV replication entirely may paradoxically increase late CMV disease through delayed immune priming. Emerging strategies, including letermovir, CMV-specific immunotherapy, and CMV vaccination in seronegative recipients, represent promising approaches requiring prospective evaluation in pediatric transplant populations[ 23 ].

Telomere dynamics and cellular senescence

Telomere attrition as a biomarker and mechanism: Telomere dysfunction emerges as both a mechanistic driver and a biomarker of accelerated immune aging in transplant recipients. Telomeres, TTAGGG repeat sequences protecting chromosome ends, shorten with each cell division, ultimately triggering replicative senescence when critically short telomeres activate DNA damage response pathways[ 24 ]. In pediatric transplant recipients, multiple factors converge to accelerate telomere attrition: Repeated T cell activation and proliferation in response to alloantigens and pathogens, oxidative stress from immunosuppressive medications, chronic inflammation, and reduced telomerase activity in immunosenescent cells[ 25 ].

Wang et al [ 26 ] demonstrated that pre-transplant short telomere length serves as a prognostic factor for post-transplant survival in patients with severe aplastic anemia undergoing HSCT, suggesting that telomere status represents a biomarker of cellular aging that influences transplant outcomes. Song et al [ 27 ] reported that childhood cancer survivors demonstrate shortened leukocyte telomere length associated with increased prevalence of chronic health conditions, establishing precedent for telomere-mediated complications in pediatric populations exposed to intensive medical interventions.

Molecular consequences of telomere dysfunction: Critically short telomeres trigger cellular senescence through activation of p53 and p16INK4a/Rb pathways, resulting in irreversible cell cycle arrest[ 28 ]. Senescent cells acquire the SASP, secreting pro-inflammatory cytokines [interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-α], growth factors, proteases, and chemokines that promote chronic inflammation and tissue dysfunction[ 29 ]. In the context of transplantation, accumulation of senescent immune cells with SASP contributes to inflammaging, potentially promoting tumorigenesis through chronic inflammation while simultaneously compromising anti-tumor immunity through exhaustion of functional immune cells.

The relationship between telomere dysfunction and cancer predisposition is complex and bidirectional. While critically short telomeres can promote genomic instability and malignant transformation through breakage-fusion-bridge cycles, Zhang et al [ 28 ] demonstrated that genetic predisposition to longer telomere length is paradoxically associated with increased ependymoma risk, suggesting that optimal telomere maintenance represents a narrow therapeutic window. This complexity underscores the need for nuanced approaches to monitoring and potentially modulating telomere dynamics in pediatric transplant recipients.

Thymic involution and T cell repertoire restriction

The central role of thymic function: Thymic dysfunction represents a fundamental mechanism driving accelerated immunosenescence in pediatric transplant recipients, with effects persisting long after transplantation. The thymus serves as the primary site for T cell development, generating naive T cells with diverse TCR specificities through somatic recombination processes[ 30 , 31 ]. Thymic output, quantifiable through TCR excision circles (TRECs) and assessment of CD45RA+ CD31+ recent thymic emigrants (RTEs), declines with age but remains substantial in healthy children and adolescents[ 32 ].

In transplant recipients, thymic function is compromised through multiple mechanisms: Direct toxic effects of conditioning chemotherapy or radiation, immunosuppressive medications [particularly corticosteroids and calcineurin inhibitors (CNIs)], chronic GVHD in HSCT recipients ( Figure 1 ), and surgical thymectomy in congenital heart disease patients undergoing cardiac surgery[ 33 ]. Mengrelis et al [ 34 ] documented persistent T cell abnormalities in pediatric heart transplant recipients, attributed to both immunosuppression and concurrent thymectomy during cardiac surgery, with reduced naive T cell proportions and decreased TREC levels years post-transplant ( Figure 1 )[ 35 ].

Consequences of impaired thymic output: Reduced thymic output results in prolonged T cell lymphopenia and skewed immune reconstitution, favoring memory over naive T cell populations[ 36 ]. Mackall et al [ 37 ] demonstrated that thymic function can be substantially impaired even in young recipients, leading to repertoire restriction and reliance on peripheral expansion mechanisms for T cell reconstitution. Kanakry et al [ 38 ] showed that T cell repertoire reconstitution after post-transplantation cyclophosphamide relies heavily on peripheral expansion rather than de novo thymic generation, potentially limiting long-term immune competence and cancer immunosurveillance capabilities.

TCR repertoire diversity and functional implications: TCR repertoire diversity is essential for recognizing the vast array of potential antigens, including pathogen-derived peptides and tumor-associated antigens. Ciupe et al [ 39 ] demonstrated that thymic transplantation can restore TCR repertoire diversity in DiGeorge syndrome patients, highlighting the critical role of functional thymic tissue in maintaining immune competence. Conversely, transplant recipients with impaired thymic function demonstrate restricted repertoires dominated by oligoclonal populations, reducing capacity for novel antigen recognition and potentially compromising tumor immunosurveillance.

Inflammaging and SASP

Chronic inflammation as a driver of aging: Inflammaging, chronic, low-grade, sterile inflammation characteristic of aging, emerges as a critical mechanism linking immunosuppression to accelerated aging and cancer predisposition[ 40 ]. Multiple sources contribute to inflammaging in transplant recipients: Senescent cells secreting SASP factors, persistent viral infections (CMV, EBV), chronic allograft inflammation, immunosuppressive medication effects, and gut dysbiosis with increased intestinal permeability and bacterial translocation[ 41 ].

Franzin et al [ 42 ] examined the complement system’s role in linking acute kidney injury to chronic graft damage through inflammaging pathways, demonstrating elevated inflammatory cytokines (IL-6, TNF-α, IL-1β) and complement activation in transplant recipients. Singh et al [ 4 ] comprehensively reviewed aging and inflammation mechanisms, emphasizing the role of innate immune activation, inflammasome activation (particularly nod-like receptor protein 3), and disrupted autophagy in perpetuating chronic inflammatory states.

SASP as a pro-tumorigenic factor: The SASP encompasses over 50 secreted factors, including IL-6, IL-8, growth-regulated oncogene-α, monocyte chemoattractant protein-1, matrix metalloproteinase-3, and others that create a pro-tumorigenic microenvironment[ 4 ]. SASP factors promote cancer development through multiple mechanisms: Stimulating proliferation of premalignant cells, inducing epithelial-mesenchymal transition, promoting angiogenesis, remodeling extracellular matrix, recruiting immunosuppressive myeloid cells, and exhausting anti-tumor T cells through chronic antigen stimulation[ 5 ]. In the context of post-transplant malignancy, SASP represents a mechanistic link between immunosenescence and cancer development independent of direct immunosuppression effects ( Figure 2 )[ 43 ].

Innate immune senescence: While most immunosenescence research focuses on adaptive immunity, innate immune aging significantly contributes to cancer predisposition. NK cells, critical for tumor immunosurveillance, undergo functional decline with aging, exhibiting reduced cytotoxicity, altered receptor expression (decreased NKG2D, increased NKG2A), and impaired proliferative capacity[ 44 ]. Macrophages demonstrate polarization toward M2 phenotypes with pro-tumorigenic and immunosuppressive functions[ 43 ]. Neutrophils show reduced chemotaxis and phagocytic capacity while exhibiting increased production of reactive oxygen species, contributing to chronic inflammation[ 45 ]. Transplant recipients demonstrate accelerated innate immune aging, warranting investigation as potential therapeutic targets.

Metabolic reprogramming and immunosenescence

Mechanistic target of rapamycin signaling and immune aging: The mechanistic target of rapamycin (mTOR) pathway emerges as a master regulator of cellular aging and immune function[ 46 ]. mTOR hyperactivation promotes cellular senescence, drives anabolic metabolism, inhibits autophagy, and accelerates aging across multiple tissues[ 47 ]. In T cells, mTOR signaling regulates differentiation, with mTOR activation driving effector T cell differentiation and memory T cell formation requiring mTOR inhibition[ 48 ].

Paradoxically, while mTOR inhibitors (rapamycin, everolimus) are used as immunosuppressants in transplantation, they may exert anti-aging effects, including enhanced autophagy, improved mitochondrial function, and reduced senescent cell accumulation[ 49 ]. Caloric restriction and ketogenic diets, which inhibit mTOR signaling, extend lifespan in multiple organisms and may offer therapeutic potential in mitigating accelerated aging in transplant recipients[ 50 ]. The complex interplay between mTOR’s immunosuppressive and anti-aging effects requires careful dissection to optimize therapeutic applications.

Mitochondrial dysfunction and oxidative stress: Mitochondrial dysfunction represents a hallmark of aging and significantly impacts immune cell function[ 51 ]. Aged T cells demonstrate reduced mitochondrial membrane potential, decreased ATP production, increased reactive oxygen species generation, and impaired mitophagy, selective autophagy of damaged mitochondria[ 52 ]. CNIs (tacrolimus, cyclosporine), commonly used immunosuppressants, induce mitochondrial dysfunction in multiple cell types, including T cells, potentially accelerating immune aging through oxidative stress pathways[ 53 ].

Reactive oxygen species, while serving important signaling functions at physiological levels, cause cumulative oxidative damage to lipids, proteins, and DNA when chronically elevated[ 54 ]. Oxidative stress accelerates telomere attrition (telomeric DNA is particularly susceptible to oxidative damage), activates senescence pathways, and promotes inflammatory signaling through nuclear factor-κB activation[ 55 ]. Mitochondrial-targeted antioxidants (MitoQ, SkQ1) represent potential therapeutic interventions to mitigate oxidative stress-driven immune aging in transplant recipients.

Nicotinamide adenine dinucleotide metabolism and sirtuins: Nicotinamide adenine dinucleotide (NAD+) serves as a critical cofactor for sirtuins (SIRTs), NAD+-dependent deacetylases regulating multiple aging pathways[ 56 ]. NAD+ levels decline with aging, contributing to mitochondrial dysfunction, impaired DNA repair, and metabolic dysregulation[ 57 ]. SIRTs, particularly SIRT1, SIRT3, and SIRT6, regulate immune cell function, promote mitochondrial health, enhance DNA repair, and suppress inflammatory signaling[ 58 ].

NAD+ precursors, including nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), restore NAD+ levels in aged animals, improving multiple aging hallmarks, including mitochondrial function, stem cell function, and cognitive performance[ 59 ]. Whether NAD+ supplementation can mitigate accelerated immune aging in pediatric transplant recipients represents an important research question with potential therapeutic implications.

Epigenetic alterations and DNA methylation clocks

Epigenetic aging in transplantation: Epigenetic modifications, particularly DNA methylation patterns, change predictably with chronological age, enabling the development of “epigenetic clocks” that estimate biological age[ 60 ]. The Horvath clock, based on the methylation status of 353 CpG sites, accurately predicts chronological age across tissues and exhibits acceleration in age-related diseases and conditions associated with accelerated aging[ 61 ]. Preliminary evidence suggests that transplant recipients, immunosuppressive medications, and chronic viral infections alter DNA methylation patterns, potentially accelerating epigenetic aging[ 62 ].

Histone modifications and chromatin remodeling: Beyond DNA methylation, histone modifications, and chromatin accessibility changes contribute to immune aging[ 63 ]. Aged T cells demonstrate altered histone acetylation and methylation patterns, affecting gene expression programs and functional capacity[ 64 ]. Immunosuppressive medications, particularly CNIs, directly affect chromatin remodeling through nuclear factor of activated T cells pathway modulation, potentially contributing to epigenetic aging acceleration[ 65 ]. Understanding epigenetic alterations in pediatric transplant recipients may identify novel biomarkers and therapeutic targets for age-related complications.

CONFOUNDING FACTORS OF POST-TRANSPLANT CANCER RISK ASSESSMENT AND ADJUSTMENT STRATEGIES

While accelerated immunosenescence represents a critical driver of increased cancer predisposition in pediatric transplant recipients, comprehensive risk assessment requires acknowledgment of multiple confounding factors that may independently or synergistically contribute to observed cancer incidence. Disentangling these interrelated contributors presents substantial methodological challenges, and few studies have adequately adjusted for the full constellation of potential confounders[ 66 , 67 ]. This section critically examines these confounding factors and evaluates how epidemiologic studies have attempted to address them.

Underlying disease and pre-transplant disease burden

The indications for transplantation themselves may confer independent cancer predisposition that predates immunosuppressive exposure. End-stage renal disease (ESRD) patients demonstrate elevated cancer risk even before transplantation, with SIRs of 1.16-1.35 in the pre-transplant period, rising to 3.27 post-transplantation[ 68 ]. This pre-existing elevation suggests that uremia, chronic inflammation associated with kidney failure, and dialysis-related factors contribute to baseline cancer risk independent of transplant-related immunosuppression.

Similarly, patients with autoimmune hepatitis or primary sclerosing cholangitis requiring liver transplantation carry elevated colorectal cancer risk associated with concurrent ulcerative colitis[ 29 , 69 ]. Chronic hepatitis B and C virus infections, common indications for liver transplantation, independently increase hepatocellular carcinoma risk through decades of hepatic inflammation and cirrhosis, complicating attribution of post-transplant liver cancers solely to immunosuppression[ 70 ].

In pediatric HSCT for non-malignant diseases such as severe aplastic anemia, Fanconi anemia, or inherited bone marrow failure syndromes, underlying genomic instability and defective DNA repair mechanisms inherent to these conditions confer independent malignancy risk[ 14 ]. Children with Fanconi anemia demonstrate a 500- to 700-fold increased risk of acute myeloid leukemia and solid tumors even without transplantation, attributable to germline mutations in DNA repair pathways[ 17 ].

Adjustment strategies: Rigorous epidemiologic studies employ several approaches to account for underlying disease effects. Landmark analyses comparing cancer incidence in the same ESRD patients across three distinct periods: Pre-renal replacement therapy, during dialysis, and post-transplantation, demonstrated progressive risk escalation that isolated transplant-specific effects from underlying kidney disease. Exclusion of cancers known to be caused by underlying conditions ( e.g. , multiple myeloma and kidney cancer in ESRD patients) from primary analyses provides conservative risk estimates[ 68 ]. However, complete adjustment remains challenging, as underlying diseases may share pathophysiologic mechanisms with immunosenescence, including chronic inflammation and immune dysregulation.

Pre-transplant chemotherapy and radiation exposure

A substantial proportion of pediatric transplant recipients, particularly HSCT recipients for malignant diseases, have prior exposure to cytotoxic chemotherapy and radiation that independently elevate subsequent malignancy risk. Alkylating agents (cyclophosphamide, busulfan) used in conditioning regimens induce DNA damage and chromosomal instability, contributing to therapy-related myelodysplastic syndromes and acute myeloid leukemia with latency periods of 3-7 years[ 18 ]. Topoisomerase II inhibitors (etoposide, doxorubicin) cause balanced chromosomal translocations predisposing to therapy-related leukemias with shorter latency (1-3 years)[ 22 ].

Radiation therapy, whether total body irradiation in conditioning regimens or therapeutic irradiation for prior malignancies, confers dose-dependent solid tumor risk with long latency periods extending decades[ 33 ]. Childhood Cancer Survivor Study data demonstrate that radiation doses exceeding 20 Gy to specific body regions increase second malignant neoplasm risk 5- to 10-fold, with risk persisting 30-40 years post-exposure[ 27 ]. Notably, cardiac surgery for congenital heart disease requiring concurrent thymectomy compounds immunologic impairment through surgical thymic ablation, synergizing with subsequent immunosuppression to accelerate immune aging[ 34 ].

The interaction between prior cytotoxic therapy and subsequent immunosuppression likely operates through multiple mechanisms: Cumulative DNA damage, telomere attrition from repeated cell cycling, stem cell exhaustion, and persistent bone marrow dysfunction that impairs immune reconstitution[ 25 ]. Critically, children transplanted for non-malignant conditions without prior chemotherapy or radiation still demonstrate markedly elevated cancer risk, confirming that immunosuppression alone suffices to drive malignancy, though prior therapy amplifies risk[ 38 ].

Adjustment strategies: Studies of HSCT recipients for non-malignant diseases ( e.g. , aplastic anemia, immunodeficiencies, hemoglobinopathies) provide natural cohorts minimizing chemotherapy/radiation confounding[ 36 ]. The CIBMTR pediatric allogeneic HSCT study of non-malignant indications ( n = 6028) demonstrated subsequent neoplasm SIR of 11, comparable to malignant indication cohorts, isolating transplant-related effects[ 12 ]. Dose-response analyses incorporating cumulative chemotherapy exposure ( e.g. , alkylating agent dose) and radiation field/dose enable risk stratification, though residual confounding from disease severity correlated with treatment intensity remains challenging to eliminate[ 27 ].

Genetic cancer predisposition syndromes

Inherited cancer predisposition syndromes may independently contribute to post-transplant malignancy risk, though their prevalence in transplant cohorts and contribution to excess cancer burden remain inadequately characterized. Germline mutations in cancer susceptibility genes occur in approximately 8%-10% of pediatric cancer patients overall[ 71 , 72 ], but systematic screening of transplant recipients for such mutations is not standard practice, precluding accurate prevalence estimation.

Li-Fraumeni syndrome (germline TP53 mutations) confers > 90% lifetime cancer risk across diverse malignancy types, with early-onset characteristics[ 24 ]. Constitutional mismatch repair deficiency (biallelic mutations in MLH1, MSH2, MSH6, PMS2) causes childhood onset of hematologic and solid malignancies[ 28 ]. Fanconi anemia, dyskeratosis congenita, and other inherited bone marrow failure syndromes requiring HSCT carry an intrinsic high malignancy risk through defective DNA repair and telomere maintenance[ 17 ]. Hereditary breast and ovarian cancer syndrome ( BRCA1 / BRCA2 mutations), while typically manifesting in adulthood, may influence cancer risk in adolescent/young adult transplant recipients followed long-term[ 30 ].

The intersection of genetic predisposition and iatrogenic immunosuppression likely produces synergistic cancer risk through complementary mechanisms: Genomic instability from germline mutations combined with impaired immunosurveillance of malignant clones. However, distinguishing cancer attributable to genetic predisposition vs immunosuppression proves challenging without comprehensive germline testing and appropriately matched comparison groups.

Adjustment strategies: Contemporary epidemiologic studies increasingly incorporate germline genetic testing, though implementation in transplant cohorts lags behind oncology populations[ 71 ]. The St. Jude PeCan Data Portal and similar efforts systematically characterize germline variants in pediatric cancer survivors, providing frameworks applicable to transplant populations[ 27 ]. Exclusion of patients with known high-penetrance cancer predisposition syndromes from primary analyses enables more precise estimation of transplant-attributable risk, while stratified analyses can characterize risk modification by genetic factors[ 30 ]. However, such exclusions may underestimate true population-level risk if genetic predisposition prevalence differs between transplant and general populations.

Environmental exposures and lifestyle factors

Post-transplant cancer risk is modified by ongoing environmental carcinogen exposure, particularly ultraviolet radiation (UVR) and oncogenic viruses. Non-melanoma skin cancer, the most common malignancy in adult transplant recipients, demonstrates strong dose-response relationships with cumulative UVR exposure, with SIRs reaching 100-fold in fair-skinned recipients with high sun exposure. Lip cancer risk, elevated 30-fold post-transplant, similarly correlates with UVR exposure and fair phenotype[ 34 ].

Oncogenic virus exposure timing and serostatus critically modify PTLD risk. EBV-seronegative recipients experiencing primary EBV infection post-transplant demonstrate PTLD risk 5- to 10-fold higher than EBV-seropositive recipients undergoing viral reactivation[ 7 ]. Human papillomavirus (HPV) infection contributes to anogenital and oropharyngeal malignancies, with higher prevalence and persistence in immunosuppressed populations. Tobacco smoking amplifies lung, oropharyngeal, and bladder cancer risk in transplant recipients, operating synergistically with immunosuppression[ 22 ].

Adjustment strategies: Comprehensive cohort studies incorporate baseline and longitudinal assessment of sun exposure behaviors, smoking history, and viral serostatus, enabling multivariable adjustment[ 72 ]. Registry-based studies increasingly link transplant registries with cancer registries and viral surveillance databases, improving confounding control[ 7 ]. However, behavioral exposures are subject to measurement error and recall bias, and viral infection status may itself be affected by immunosuppression (reverse causation). Propensity score matching based on measured confounders provides one approach to balance exposure distributions between transplant recipients and comparison groups[ 5 ].

Longevity bias and immortal time bias

Methodological biases inherent to transplant outcome research may artificially inflate or deflate cancer risk estimates. Longevity bias (survivor treatment selection bias) arises because transplant recipients must survive long enough to receive transplantation, excluding the sickest patients who die while waitlisted. This selection process creates a survivor cohort healthier than the overall waitlisted population, potentially underestimating cancer risk if pre-existing occult malignancies or frailty associated with cancer predisposition cause waitlist mortality[ 40 ].

Conversely, transplant recipients undergo more intensive medical surveillance than the general population, increasing detection of asymptomatic cancers that might otherwise remain undiagnosed (surveillance bias). Routine imaging for graft assessment, frequent laboratory monitoring, and heightened clinical vigilance for infectious and malignant complications create opportunities for incidental cancer detection. This detection bias likely contributes to apparently elevated rates of renal cell carcinoma and thyroid cancer, tumors frequently discovered incidentally on imaging obtained for other indications[ 41 ].

Immortal time bias poses a particularly insidious threat to validity in observational transplant research[ 46 ]. This bias occurs when follow-up time during which the outcome (cancer) cannot occur by definition is inappropriately included in the exposed group’s follow-up. For example, comparing cancer rates in transplant recipients vs waitlisted patients without accounting for time spent on the waitlist before transplantation assigns “immortal time” to the transplanted group, as patients must survive waitlist duration cancer-free to receive a transplant, artificially lowering their apparent cancer rate[ 47 ].

Adjustment strategies: Landmark analysis addresses longevity bias by defining cohort entry at a common time point ( e.g. , 1-year post-transplant), excluding early events and patients who die before the landmark[ 32 ]. This approach sacrifices early follow-up data but ensures comparable survivor populations. Time-dependent covariate analysis and immortal time risk-period adjustment using time-varying exposure definitions prevent immortal time bias by correctly allocating person-time to exposed vs unexposed status[ 46 , 47 ]. Sensitivity analyses excluding cancers likely subject to surveillance bias ( e.g. , incidentally detected small renal masses) test the robustness of findings.

Surveillance intensity and detection bias

The intensity and modality of cancer surveillance in transplant recipients exceeds that in the general population, introducing systematic differences in cancer detection that confound true incidence comparisons. Transplant protocols mandate frequent clinic visits, comprehensive laboratory panels including tumor markers, and routine cross-sectional imaging to assess graft function and detect complications[ 33 ]. This intensive surveillance creates opportunities for incidental cancer detection substantially exceeding the general population’s exposure to diagnostic procedures.

Detection bias particularly affects tumors amenable to imaging or laboratory-based detection: Renal cell carcinoma (detected on routine abdominal imaging), thyroid cancer (detected on neck imaging), and early-stage hepatocellular carcinoma (detected by surveillance ultrasound and alpha-fetoprotein monitoring)[ 73 ]. Yanik et al [ 7 ] noted that although thyroid cancer SIR was elevated 6-fold post-transplant, mortality from thyroid cancer was not increased, suggesting detection of indolent cancers that would not have caused clinical harm, classic overdiagnosis.

Conversely, certain cancers may be underdetected in transplant populations despite elevated true incidence. Prostate-specific antigen screening is complicated in chronic kidney disease patients by impaired antigen clearance, leading to artificially elevated prostate-specific antigen levels and diagnostic confusion, potentially reducing screening uptake[ 58 ]. Mammography interpretation is confounded by increased breast calcifications associated with renal disease and transplant medications[ 48 ]. These factors may explain the paradoxical absence of increased breast and prostate cancer in transplant cohorts despite immunosuppression that should theoretically impair tumor immunosurveillance[ 74 ].

Adjustment strategies: Calculating cancer-specific mortality in addition to incidence helps distinguish true increased risk from overdiagnosis[ 75 ], as aggressive cancers drive mortality, whereas indolent overdiagnosed cancers do not[ 7 ]. Excluding cancers with high probabilities of incidental detection (small renal masses, papillary thyroid microcarcinomas) in sensitivity analyses tests whether excess risk persists. Comparing cancer stage distribution between transplant recipients and the general population reveals detection bias: Stage shift toward earlier stages suggests surveillance-related detection, whereas similar or later stage distribution indicates true increased incidence of clinically significant disease. However, complete elimination of detection bias remains elusive without impractical randomized trials with standardized surveillance protocols[ 76 ].

Temporal trends and era effects

Cancer risk after transplantation has evolved substantially across transplant eras, reflecting advances in immunosuppressive regimens, antiviral prophylaxis, graft preservation techniques, and patient selection[ 3 ]. Early transplant cohorts (1970s-1980s) received azathioprine-based immunosuppression with limited viral monitoring, experiencing extremely high PTLD rates. Introduction of cyclosporine (1980s), tacrolimus (1990s), and mycophenolate mofetil (late 1990s) altered both rejection rates and malignancy profiles[ 23 ].

Adoption of universal CMV prophylaxis with (val)ganciclovir and widespread EBV viral load monitoring in the 2000s reduced early PTLD incidence in some cohorts, though late-onset disease persists[ 23 , 77 ]. Conversely, prolonged survival enabled by improved graft outcomes increases person-time at risk for late malignancies, potentially elevating long-term cancer incidence despite improved short-term outcomes[ 10 ]. Registry-based studies spanning decades must account for these temporal trends, as crude incidence comparisons across eras conflate true changes in cancer risk with evolving practice patterns, patient populations, and follow-up duration[ 8 ]. Failure to adjust for era effects may produce misleading conclusions about cancer trends.

Adjustment strategies: Stratified analyses by transplant era with era-specific SIRs account for changing background cancer rates in the general population[ 7 ]. Multivariable models incorporating transplant year as a continuous or categorical covariate enable statistical adjustment, while interaction terms test whether risk factors’ effects vary across eras[ 26 ]. Restriction to contemporary cohorts ( e.g. , post-2000) improves generalizability to current practice but sacrifices long-term follow-up necessary to capture late malignancies[ 38 ].

Current state of confounding adjustment in the literature

Despite recognition of these multifaceted confounders, few published studies achieve comprehensive adjustment. The largest registry-based studies linking transplant registries to cancer registries ( e.g. , Yanik et al ’s Transplant Cancer Match Study of 175732 transplants[ 7 ]) provide unparalleled sample size and unbiased cancer ascertainment but lack granular data on underlying disease severity, pre-transplant therapies, genetic factors, and environmental exposures[ 7 ]. These studies calculate SIRs adjusted for age, sex, race, and calendar period but cannot adjust for unmeasured confounders.

Single-center cohort studies with detailed clinical data enable multivariable adjustment but suffer from limited sample size, potential referral bias, and voluntary cancer reporting that may miss cases[ 33 ]. Emerging linked registry approaches combining transplant registries, cancer registries, health administrative databases, and biobanks with germline sequencing hold promise for comprehensive confounding adjustment while maintaining population-based rigor[ 49 ].

Critically, even the most sophisticated adjustment strategies cannot fully address unmeasured confounding or confounding by indication (wherein disease severity drives both treatment intensity and cancer risk through shared pathways)[ 4 ]. Recognizing these limitations, the field increasingly emphasizes triangulation: Converging evidence from complementary study designs (registry linkages, detailed cohort studies, natural experiments like transplant failure cohorts) that collectively strengthen causal inference despite individual studies’ limitations[ 10 , 68 ].

Implications for immunosenescence paradigm: While confounding factors clearly contribute to post-transplant cancer risk, several lines of evidence support immunosenescence as a primary driver rather than merely a correlate of confounding. First, cancer risk demonstrates dose-response relationships with immunosuppression intensity and duration, independent of underlying disease[ 59 ]. Second, cancer risk reverses upon graft failure and immunosuppression withdrawal, inconsistent with persistent confounders[ 34 ]. Third, the malignancy spectrum, dominated by EBV-driven lymphoproliferative disease, virus-associated epithelial cancers, and immunogenic tumors, mirrors patterns in other immunodeficiency states [human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome, primary immunodeficiencies], suggesting immunosurveillance failure as a unifying mechanism. Fourth, pediatric recipients transplanted for non-malignant conditions without prior chemotherapy/radiation demonstrate cancer risk comparable to those with prior therapy, confirming sufficiency of immunosuppression alone[ 12 , 36 ].

Nonetheless, comprehensive cancer risk stratification must integrate immunosenescence biomarkers with assessment of confounding factors, underlying disease, prior therapies, genetic predisposition, environmental exposures, and surveillance intensity, to achieve precision in individual patient prognostication and population-level risk estimation. Future research prioritizing comprehensive covariate collection, germline sequencing, longitudinal biomarker assessment, and appropriate statistical methods will refine understanding of immunosenescence’s mechanistic role while acknowledging the multifactorial reality of post-transplant oncogenesis.

MECHANISMS OF CANCERS FOLLOWING ACCELERATED IMMUNE AGING

T cell exhaustion and immune evasion

Molecular mechanisms of T cell exhaustion: T cell exhaustion represents a state of functional hyporesponsiveness characterized by progressive loss of effector functions, elevated expression of multiple inhibitory receptors [programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), T-cell immunoglobulin and mucin domain-containing protein 3, lymphocyte-activation gene 3, T-cell immunoreceptor with Ig and ITIM domains], altered transcriptional programming, and metabolic dysfunction[ 78 ]. Angeletti et al [ 79 ] comprehensively reviewed T cell exhaustion in organ transplantation, demonstrating how chronic alloantigen exposure combined with immunosuppressive medications promotes exhausted T cell phenotypes with impaired anti-tumor capacity.

The transcriptional program of exhausted T cells is regulated by specific transcription factors, particularly TOX and TOX2, which establish and maintain the exhausted state[ 80 ]. Exhausted T cells exhibit epigenetic modifications that stabilize their dysfunction, creating a distinct differentiation state rather than simply a dysfunctional version of effector T cells[ 81 ]. Critically, exhausted T cells demonstrate reduced ability to eliminate malignant cells through impaired cytotoxic function, decreased proliferative capacity, and altered cytokine production, creating permissive conditions for tumor development and progression.

Multi-lineage exhaustion in transplantation

Shahbazi et al [ 82 ] highlighted that exhaustion affects multiple lymphocyte populations in transplantation, including CD4+ T cells, CD8+ T cells, B cells, and NK cells, creating comprehensive immune dysfunction extending beyond traditional immunosuppression. Das et al [ 71 ] demonstrated that naive T cell deficits present at diagnosis and exacerbated by chemotherapy significantly impair adoptive cell therapy potential in pediatric cancers, findings directly relevant to transplant recipients, where similar mechanisms of T cell depletion and dysfunction compromise natural anti-tumor responses.

Bailur et al [ 72 ] identified risk-associated alterations in marrow T cells in pediatric leukemia, including increased exhaustion markers and reduced effector function, suggesting that immune dysfunction can both predispose to malignancy and complicate treatment responses. In transplant recipients, the combination of chronic immunosuppression, viral reactivation, and persistent alloantigen exposure creates ideal conditions for progressive T cell exhaustion with consequent cancer predisposition[ 83 , 84 ].

PTLD

Epidemiology and risk factors: PTLD represents the paradigmatic malignancy illustrating the intersection of immunosenescence and cancer predisposition in pediatric transplant recipients. Using United States registry linkage data, PTLD/NHL risk is markedly elevated but heterogeneous by organ; Yanik et al [ 7 ] reported NHL/PTLD SIRs of 159 (kidney), 197 (liver), 318 (heart/Lung), and 1280 (intestine), with the greatest excess risk in the first post-transplant year and in EBV-seronegative recipients. The incidence of PTLD varies by organ type: Approximately 1%-5% in kidney recipients, 2%-5% in liver recipients, 2%-10% in heart recipients, and up to 10%-20% in intestinal transplant recipients[ 71 ].

Allen et al [ 85 ] identified critical risk factors for PTLD development, including EBV seronegativity at transplant (donor-positive/recipient-negative mismatch conferring the highest risk), young age (particularly < 5 years), intensive immunosuppression (especially ATG induction), and specific immunosuppressive agents (tacrolimus associated with higher risk than cyclosporine)[ 81 ]. These risk factors converge with mechanisms of accelerated immunosenescence: EBV-naive recipients require de novo immune responses that may be compromised by thymic dysfunction, T cell depletion, and exhaustion.

Pathogenesis of PTLD: Fulchiero and Amaral[ 86 ] emphasized that pediatric PTLD predominantly involves EBV-driven B cell proliferation, with over 80% of early PTLD cases being EBV-positive. EBV immortalizes B cells through expression of latency-associated proteins (LMP1, LMP2A, EBNA1, EBNA2, EBNA3A/B/C) that dysregulate cell cycle control, inhibit apoptosis, and promote proliferation[ 87 ]. Control of EBV-infected B cells requires robust CD8+ T cell responses targeting viral antigens; immunosenescence-associated reductions in naive T cells, TCR repertoire restriction, and T cell exhaustion fundamentally compromise this control mechanism.

Tajima et al [ 76 ] provided contemporary prospective data demonstrating persistently elevated PTLD risk despite advances in immunosuppressive protocols and viral monitoring, with EBV viral load monitoring improving early detection but not eliminating disease occurrence. Jia et al [ 88 ] characterized risk factors for EBV reactivation and progression to PTLD, identifying high EBV viral loads (> 10000 copies/mL), rapid viral load increases, and concurrent CMV infection as predictive factors. The management approaches described by Green et al [ 89 ] emphasize immunosuppression reduction as primary therapy, with rituximab, chemotherapy, and adoptive immunotherapy reserved for refractory cases, underscoring the fundamental relationship between immune competence and PTLD control.

Immunosurveillance failure and solid tumor development

Spectrum of post-transplant malignancies: Beyond lymphoproliferative disorders, pediatric transplant recipients demonstrate an increased incidence of solid tumors, suggesting broad-based immunosurveillance failure associated with accelerated immune aging. Yanik et al [ 7 ] documented elevated risks for renal cell carcinoma (SIR 15.5), thyroid cancer (SIR 6), and hepatocellular carcinoma, with risk profiles substantially exceeding age-matched healthy populations. Kitchlu et al [ 8 ] reported that childhood SOT recipients demonstrate an overall cancer SIR of 5.5, with risks increasing with duration of follow-up, suggesting cumulative effects of chronic immunosuppression and progressive immunosenescence ( Table 1 ).

Endén et al [ 10 ] documented cancer incidence of 8% in Finnish pediatric SOT recipients with a median follow-up of 11 years, emphasizing the need for lifelong cancer surveillance. The spectrum of malignancies parallels that observed in elderly populations, including increased skin cancers (basal cell carcinoma, squamous cell carcinoma, melanoma), kidney cancers, and anogenital cancers associated with oncogenic viruses (HPV).

Mechanisms of immunosurveillance failure: The cancer immunosurveillance hypothesis, extensively validated through experiments in immunodeficient mice and clinical observations in immunosuppressed patients, posits that the immune system continuously recognizes and eliminates nascent malignant cells[ 8 ] Effective immunosurveillance requires: (1) Tumor antigen presentation by MHC molecules; (2) Recognition by T cells with appropriate TCR specificities; (3) Robust effector T cell responses with cytotoxic function; (4) NK cell-mediated killing of cells with downregulated MHC; and (5) Adequate inflammatory signaling to recruit and activate immune cells[ 10 ].

Accelerated immunosenescence in pediatric transplant recipients compromises multiple aspects of this multi-layered surveillance system. Reduced naive T cell populations and restricted TCR repertoires limit recognition of tumor neoantigens. Exhausted T cells demonstrate impaired cytotoxic function even when tumor antigens are recognized. Senescent NK cells exhibit reduced cytotoxicity. Chronic inflammation from inflammaging and SASP creates paradoxically immunosuppressive tumor microenvironments through recruitment of myeloid-derived suppressor cells and regulatory T cells[ 69 ].

Viral-associated malignancies: A substantial proportion of post-transplant malignancies are associated with oncogenic viruses, reflecting the dual role of immunosenescence in promoting both viral reactivation and reduced anti-tumor immunity. EBV associates with PTLD, nasopharyngeal carcinoma, and gastric carcinoma. HPV is associated with anogenital cancers and skin cancers. Kaposi sarcoma herpesvirus (KSHV/HHV-8) associates with Kaposi sarcoma and primary effusion lymphoma. Hepatitis B and C viruses associate with hepatocellular carcinoma[ 90 ].

Viral oncogenesis requires chronic infection with insufficient immune control, allowing accumulation of infected cells and progressive malignant transformation. The accelerated immune aging in transplant recipients facilitates viral persistence through compromised T cell responses, creating ideal conditions for virus-associated cancer development. This mechanism is particularly relevant in pediatric recipients where EBV and HPV seroconversion often occurs post-transplant during periods of peak immunosuppression[ 90 ].

Role of microenvironment and SASP in tumor promotion

Beyond direct immunosurveillance failure, the pro-inflammatory microenvironment created by senescent cells actively promotes tumorigenesis[ 91 ]. SASP factors, including IL-6, IL-8, and growth-regulated oncogene-α, stimulate proliferation of premalignant cells through signal transducer and activator of transcription 3 and mitogen-activated protein kinases signaling[ 92 ]. Matrix metalloproteinases secreted by senescent cells remodel the extracellular matrix, facilitating invasion and metastasis[ 93 ]. Vascular endothelial growth factor and other angiogenic factors promote tumor vascularization. Chemokines recruit immunosuppressive myeloid cells that inhibit anti-tumor T cell responses[ 94 ].

This pro-tumorigenic microenvironment, combined with compromised immunosurveillance, creates a “perfect storm” for cancer development in pediatric transplant recipients. Senescent cells accumulate due to chronic inflammation, oxidative stress, and telomere dysfunction. These cells establish local and systemic pro-inflammatory environments that both promote malignant transformation and impair anti-tumor immunity, mechanistically linking immunosenescence to cancer predisposition independent of direct immunosuppression effects.

BIOMARKERS OF IMMUNE AGING

Flow cytometric immunophenotyping

T cell senescence markers: Flow cytometric assessment of T cell senescence markers represents the most accessible and clinically applicable biomarker approach. Key markers include: CD28 loss. CD28, a costimulatory receptor essential for T cell activation, is progressively lost with repeated activation and aging. CD4+ CD28 null and CD8+ CD28 null T cells exhibit reduced proliferative capacity, shortened telomeres, and increased pro-inflammatory cytokine production[ 95 ]. Schaenman et al [ 96 ] demonstrated significant elevation of CD28-negative T cells in older kidney transplant recipients, with proportions correlating with age and clinical outcomes. Dedeoglu et al [ 97 ] showed that CD28 loss on peripheral T cells paradoxically correlates with decreased acute rejection risk, suggesting that immunosenescence biomarkers may guide immunosuppression intensity. Killer cell lectin-like receptor G1 expression: Killer cell lectin-like receptor G1 (KLRG1) marks terminally differentiated effector cells with limited proliferative capacity and short lifespan[ 98 ]. KLRG1+ T cells accumulate with aging and chronic viral infections, serving as markers of replicative senescence and exhaustion. CD57 expression: CD57 identifies highly differentiated T cells with reduced proliferative capacity and telomerase activity, accumulating preferentially in CMV-seropositive individuals[ 99 ]. CD28- CD57+ T cells represent the most senescent population with the poorest functional capacity. CD45RA+ CCR7- (TEMRA) cells: Terminally differentiated effector memory T cells re-expressing CD45RA represent end-stage differentiation with exhausted phenotypes[ 100 ].

RTEs and thymic function: Assessment of thymic output provides critical information about regenerative capacity. CD4+ CD45RA+ CD31+ cells represent RTEs, with CD31 expression distinguishing thymus-derived from peripherally expanded naive T cells[ 101 ]. Reduced RTE proportions indicate impaired thymic function and predict inferior immune reconstitution. TRECs, episomal DNA byproducts of TCR gene rearrangement, quantify thymic output, with low TREC levels indicating reduced thymic function[ 102 ].

Telomere length measurement

Leukocyte telomere length measurement provides a biomarker of cumulative cellular replication and biological aging. Multiple methodologies exist: Flow-fluorescence in situ hybridization. Flow cytometry with fluorescence in situ hybridization enables telomere length measurement in specific cell populations, revealing heterogeneity across lymphocyte subsets[ 103 ]. This approach demonstrated shortened telomeres in transplant recipients, correlating with clinical outcomes. Quantitative polymerase chain reaction (qPCR): QPCR provides high-throughput telomere length measurement, though it measures average telomere length across all cells without population-specific resolution[ 73 ]. Terminal restriction fragment analysis: Southern blot-based approach provides a gold standard measurement but requires substantial DNA and is labor-intensive[ 104 ]. Wang et al [ 26 ] demonstrated that pre-transplant short telomere length predicts post-transplant survival in severe aplastic anemia patients, validating telomere length as a clinically relevant biomarker. Song et al [ 27 ] showed that childhood cancer survivors with shortened telomeres demonstrate increased chronic health conditions, establishing precedent for telomere-based risk stratification in pediatric populations.

Inflammatory biomarkers and cytokine profiling

Chronic low-grade inflammation (inflammaging) can be quantified through circulating cytokine and acute phase reactant measurement: Pro-inflammatory cytokines. Elevated IL-6, TNF-α, IL-1β, and IL-18 characterize inflammaging and predict adverse outcomes, including cancer, cardiovascular disease, and mortality in elderly populations[ 105 ]. Similar elevations in pediatric transplant recipients may identify those with accelerated aging trajectories. C-reactive protein: Chronically elevated high-sensitivity C-reactive protein reflects systemic inflammation and predicts adverse outcomes. sCD163 and sCD14: Soluble markers of monocyte/macrophage activation correlate with inflammation and predict transplant outcomes[ 106 ]. Petrara et al [ 77 ] demonstrated that immune activation, exhaustion, and senescence profiles predict cancer development in liver transplant patients, providing proof-of-concept for biomarker-based risk stratification.

Epigenetic clocks

DNA methylation-based epigenetic clocks provide integrative biological aging measurements: Horvath multi-tissue clock. Predicts chronological age with high accuracy across tissues; acceleration predicts mortality and age-related diseases[ 63 ]. Hannum blood clock: Specific for blood cells; acceleration associates with mortality and aging phenotypes[ 66 ]. PhenoAge and GrimAge: Second-generation clocks trained on clinical phenotypes and mortality, providing superior prediction of health outcomes compared to first-generation clocks[ 103 , 107 ]. Preliminary evidence suggests transplant recipients demonstrate epigenetic age acceleration, though pediatric-specific data remain limited. Prospective studies quantifying epigenetic aging trajectories in pediatric transplant recipients and correlating with cancer outcomes represent critical research priorities.

Functional immune assays

Beyond static biomarkers, functional assays assess immune competence: T cell proliferation assays. Measure T cell proliferative responses to mitogens (PHA, ConA) or antigens, providing functional assessment of T cell capacity[ 108 ]. Cytokine production assays: Intracellular cytokine staining or ELISpot quantifies effector cytokine production (interferon-γ, TNF-α, IL-2), revealing functional exhaustion[ 109 ]. Cytotoxicity assays: Assess CD8+ T cell and NK cell killing capacity against target cells[ 110 ]. TCR repertoire sequencing: Next-generation sequencing of TCR β and α chains quantifies repertoire diversity, identifying oligoclonal expansions and repertoire restrictions associated with immunosenescence[ 111 ].

Integrated biomarker panels

No single biomarker captures the multidimensional nature of immunosenescence. Integrated panels combining phenotypic markers (CD28, KLRG1, CD57), functional assessments (TREC levels, proliferation capacity), telomere length, inflammatory cytokines, and potentially epigenetic clocks provide comprehensive immune aging assessments. Machine learning approaches integrating multiple biomarkers may enable superior risk stratification compared to individual markers, identifying transplant recipients at the highest cancer risk for intensified surveillance or preventive interventions.

Roadmap for clinical translation: Standardization, pediatric reference ranges, and longitudinal interpretation

Standardization and reproducibility (minimum reporting and quality control): Translation of immunosenescence biomarkers into pediatric transplant care requires rigorous assay harmonization across centers to ensure reproducibility, especially because small shifts in marker prevalence can drive clinical classification.

Specimen requirements and preferred assays (what to measure, how to measure). (1) Flow cytometry immunophenotyping is the preferred first-line platform for clinical-scale immune-age monitoring because it enables simultaneous quantification of naive and differentiated subsets and senescence markers already highlighted in this review ( e.g. , loss of CD28, gain of CD57 and KLRG1, TEMRA phenotypes, and exhaustion markers such as PD1). For flow cytometry, laboratories should predefine specimen type (whole blood vs peripheral blood mononuclear cell), anticoagulant, processing time, storage/transport temperature, and freeze-thaw exposure; instrument quality control (daily quality control beads and longitudinal tracking); antibody clone/fluorochrome panels and titration; and compensation controls and gating controls (including viability dye and fluorescence-minus-one controls for dim/inhibitory markers). A practical expectation is that all publications and protocols provide a complete gating strategy and core instrument settings to permit cross-study comparison ( i.e. , “minimum information” approaches for cytometry) to support multi-center benchmarking and eventual clinical accreditation[ 112 , 113 ]. We recommend reporting markers both as percent of parent gate and absolute counts (when complete blood count or beads are available), because immunosuppression and lymphopenia can artifactually inflate percentages[ 114 - 116 ]; (2) Telomere assays should be selected based on purpose: QPCR is cost-effective for large-scale screening but provides relative average length and is sensitive to pre-analytic and extraction variability; flow-fluorescence in situ hybridization provides cell-subset-specific telomere readouts but requires fresh viable cells and specialized infrastructure; and southern/terminal restriction fragment approaches remain reference methods but are lower throughput. When the clinical concern is “critically short telomeres” (risk stratification rather than mean telomere length), single-telomere approaches ( e.g. , STELA-type methods) offer high resolution but are less scalable and typically confined to specialized laboratories[ 117 , 118 ]; and (3) Epigenetic clocks provide an integrative measure of biological aging, but results depend strongly on tissue source and clock selection. First-generation clocks (Horvath, Hannum) were trained to predict chronological age, while second-generation clocks (PhenoAge, GrimAge) were trained to predict age-associated morbidity and mortality, with GrimAge showing superior predictive performance. In pediatrics, interpretation must explicitly consider that methylation dynamics are developmentally nonlinear; therefore, where feasible, pediatric-validated clocks (or pediatric-appropriate calibration) should be prioritized over clocks trained solely in adults[ 119 ].

Pediatric reference data and normative ranges (what “abnormal” means in children): A central barrier to clinical adoption is the lack of consensus pediatric reference ranges for key immunosenescence readouts[ 116 ]. Many markers used in adults ( e.g. , frequency of CD28- or CD57+ T cells, KLRG1+ terminal differentiation, PD-1 expression intensity, and shifts in CD45RA/RO-defined naive/memory compartments) vary substantially with age, intercurrent infection, and vaccine history, and their “expected” levels differ across infancy, childhood, and adolescence. Therefore, clinical programs should: (1) Establish age-stratified local reference distributions ( e.g. , by narrow age bands)[ 116 ]; (2) Record CMV serostatus/reactivation history as a major covariate (given its known imprint on differentiated CD8 compartments); and (3) Define interpretive outputs as age-adjusted percentiles or z-scores rather than single universal cutoffs[ 19 ]. These steps are prerequisites for defensible “threshold-based interventions”, which the clinical framework in this review advocates.

Clinical thresholds and longitudinal interpretation (how to use results over time): Single-time-point testing can be misleading in transplant recipients because immunosuppression intensity, viral reactivation, and lymphocyte depletion/reconstitution can cause transient excursions. We therefore recommend interpreting immune-age biomarkers longitudinally, anchored to: (1) Each patient’s baseline (pre-transplant if available); (2) Clinically meaningful events (ATG exposure, rejection treatment pulses, CMV/EBV episodes); and (3) Trajectories rather than absolute values. Operationally, programs can define “concerning change” as persistent deviation beyond an age-adjusted reference band across ≥ 2 sequential time points, or a sustained directional shift ( e.g. , progressive loss of naïve compartments with expansion of terminally differentiated or exhausted phenotypes), rather than reacting to isolated results. This longitudinal approach aligns with the review’s proposal for serial post-transplant monitoring and threshold-triggered interventions while reducing false alarms[ 19 ].

Cost and feasibility (real-world deployment): From a scalability standpoint, flow cytometry immunophenotyping is typically the most implementable option in tertiary pediatric transplant centers (existing cytometry cores), whereas telomere and methylation assays may require batching, external laboratories, and additional cost. A pragmatic stepwise approach is: (1) Low-cost, high-frequency monitoring with standardized flow cytometry panels; (2) Targeted telomere or epigenetic assays for patients with discordant phenotypes, high-risk clinical trajectories, or research protocols; and (3) Iterative refinement of thresholds based on outcomes (infection burden, malignancy, graft survival).

THERAPEUTIC STRATEGIES FOR IMMUNOSENESCENCE CANCER RISK MITIGATION

Across all proposed interventions, pediatric-specific pharmacology, potential interactions with baseline immunosuppression, the risk of destabilizing graft tolerance (rejection/GVHD), risk of latent virus reactivation, and unknown long-term developmental effects must be considered explicitly; therefore, most approaches should be biomarker-guided and trial-based rather than empiric.

Age-adapted immunosuppression strategies

Rationale for personalized immunosuppression: The recognition of accelerated immune aging in pediatric transplant recipients necessitates fundamental reconsideration of immunosuppressive protocols. Traditional one-size-fits-all approaches fail to account for: (1) Pre-existing immune status at transplant; (2) Progressive immunosenescence developing post-transplant; (3) Individual variability in immune aging trajectories; and (4) Changing immune status over years to decades post-transplant[ 3 ].

Krenzien et al [ 3 ] provided a comprehensive rationale for age-adapted immunosuppression, emphasizing that aging affects immune responses in ways requiring specific therapeutic considerations. While this framework was developed primarily for elderly recipients, the principles apply equally to pediatric recipients with accelerated immune aging who may exhibit immune profiles resembling those of elderly individuals despite chronological youth.

Immunosuppression minimization and withdrawal: In recipients with established immunosenescent phenotypes, elevated CD28-negative T cells, reduced naive T cell populations, exhaustion markers, immunosuppression reduction may be feasible without increased rejection risk. Dedeoglu et al [ 97 ] demonstrated that CD28 loss correlates with decreased acute rejection risk, suggesting immunosenescence markers could guide immunosuppression tapering. Conversely, recipients maintaining robust immune function may require standard immunosuppression to prevent rejection.

CNI avoidance or withdrawal represents an attractive strategy given CNI nephrotoxicity, neurotoxicity, diabetogenicity, and potential immune aging effects. Harmon et al [ 120 ] demonstrated the feasibility of CNI avoidance in pediatric renal transplantation using daclizumab induction, sirolimus, and corticosteroids, achieving comparable rejection rates with potential advantages for long-term graft function. Liu and Mao[ 121 ], along with Karolin et al [ 122 ], documented CNI nephrotoxicity in children, providing rationale for CNI-sparing approaches.

mTOR inhibitors (sirolimus, everolimus) offer theoretical advantages through anti-aging effects, including enhanced autophagy, reduced senescent cell accumulation, and potential anti-tumor properties. However, these benefits must be balanced against side effects, including hyperlipidemia, impaired wound healing, and potential bone marrow suppression. Prospective trials comparing CNI-based and mTOR inhibitor-based regimens with immunosenescence biomarker monitoring are needed to optimize immunosuppression strategies.

Senolytic and senomorphic therapies

Senolytics, eliminating senescent cells: Senolytics selectively eliminate senescent cells, which accumulate with aging and contribute to age-related pathology through SASP[ 123 ]. Multiple senolytic combinations have demonstrated efficacy in preclinical models: Dasatinib + quercetin (D + Q). This combination demonstrates broad senolytic activity across cell types. Dasatinib, a tyrosine kinase inhibitor, targets senescent adipocytes and other cells, while quercetin (a flavonoid) eliminates senescent endothelial cells[ 124 ]. In aged mice, D + Q treatment reduced senescent cell burden, decreased inflammatory cytokines, improved physical function, and extended healthspan[ 125 ]. Clinical trials in humans with idiopathic pulmonary fibrosis, diabetic kidney disease, and Alzheimer’s disease are ongoing[ 126 ]. Fisetin: A flavonoid with senolytic properties demonstrated to reduce senescent cell burden and extend healthspan in mice[ 127 ]. Fisetin may offer the advantages of single-agent therapy with a good safety profile. Navitoclax (ABT-263): A B cell lymphoma-2 family inhibitor with potent senolytic activity, particularly against senescent hematopoietic and immune cells[ 128 ]. However, on-target thrombocytopenia limits clinical utility, though intermittent dosing schedules may mitigate this toxicity.

Application of senolytics in pediatric transplant recipients represents a promising but unexplored therapeutic avenue. Senescent immune cells contributing to inflammaging and compromised immunosurveillance could be targeted for elimination, potentially restoring immune function. Critical questions include optimal timing (preventive vs therapeutic), dosing schedules, and safety in immunosuppressed populations. Proof-of-concept trials measuring senescence biomarkers and immune function pre- and post-senolytic treatment are warranted.

Senomorphics, suppressing SASP: Senomorphics modulate senescent cell function, particularly suppressing SASP, without necessarily eliminating senescent cells. Key senomorphics include: Rapamycin and rapalogs. mTOR inhibition suppresses SASP through multiple mechanisms, including nuclear factor-κB pathway inhibition[ 129 ]. As these agents are already used as immunosuppressants in transplantation, their potential senomorphic effects represent an unrecognized benefit warranting investigation. Metformin: The widely-used diabetes medication demonstrates anti-aging effects in preclinical models, including reduced inflammation, improved mitochondrial function, and potentially reduced senescent cell accumulation[ 130 ]. Observational studies suggest that metformin users demonstrate reduced cancer incidence and mortality[ 131 ]. Metformin’s safety profile and low cost make it attractive for clinical translation in transplant recipients, though rigorous trials are needed. Janus kinases (JAK) inhibitors: Inhibition of JAK/signal transducer and activator of transcription protein signaling suppresses SASP cytokine production and inflammation[ 132 ]. Ruxolitinib and other JAK inhibitors demonstrate efficacy in inflammatory conditions; their potential application in transplant-associated immunosenescence warrants investigation. P38 mitogen-activated protein kinases inhibitors: P38 regulates SASP production; inhibition reduces inflammatory cytokine secretion from senescent cells[ 133 ]. Although clinical development of p38 inhibitors has faced challenges, selective inhibitors may offer therapeutic benefits.

Risk-benefit and pediatric safety considerations: While senolytics/senomorphics could theoretically reduce SASP-driven inflammaging and improve immune surveillance[ 134 ], the transplant-pediatric context requires a higher safety bar[ 135 ]. In immunosuppressed children, additional cytopenias or impaired tissue repair may translate into serious infectious and wound-healing complications, and off-target effects on developing tissues (growth plate, endocrine maturation, neurodevelopment) remain largely unknown because most experience is derived from adult/aging models[ 136 , 137 ]. For agents with known on-target toxicities ( e.g. , thrombocytopenia with B cell lymphoma-2 family inhibition)[ 138 , 139 ], intermittent dosing and stringent hematologic monitoring would be essential[ 135 ], and any use should be restricted to carefully designed trials with age-appropriate pharmacokinetic/pharmacodynamic endpoints and long-term follow-up for growth, fertility, and secondary malignancy risk[ 137 , 140 ].

Thymic regeneration strategies

Cytokine-based approaches: Restoration of thymic function represents a fundamental strategy to combat accelerated immune aging by enhancing naive T cell generation and TCR repertoire diversity. IL-7 therapy: IL-7 promotes thymopoiesis, enhances peripheral T cell expansion, and improves T cell function[ 141 ]. Clinical trials in HIV infection and cancer demonstrated IL-7 therapy increases CD4+ and CD8+ T cell counts, enhances thymic output (measured by TREC increases), and improves T cell function[ 142 ]. In the transplant setting, carefully dosed IL-7 could potentially enhance immune reconstitution, though concerns about triggering rejection or GVHD require cautious investigation. Growth hormone and insulin-like growth factor-1 (IGF-1): Growth hormone administration enhances thymic function and T cell reconstitution in HIV-infected individuals and following bone marrow transplantation[ 143 ]. Growth hormone effects are mediated partly through IGF-1, which promotes thymic epithelial cell function. However, concerns about potential tumor-promoting effects, particularly in cancer survivors, warrant careful consideration. Keratinocyte growth factor (KGF): KGF promotes thymic epithelial cell proliferation and protects against chemotherapy- and radiation-induced thymic damage[ 144 ]. Palifermin (recombinant KGF) is Food and Drug Administration-approved for preventing mucositis in HSCT recipients; its thymoprotective effects suggest potential utility in SOT.

Stem cell and regenerative approaches: Thymic tissue transplantation. Transplantation of cultured thymic tissue successfully restores T cell immunity in DiGeorge syndrome patients with congenital athymia[ 145 ]. While not applicable to most transplant recipients, this approach validates the principle that thymic tissue can successfully engraft and generate functional T cell repertoires. Bioengineered thymic organoids represent a potential future source of transplantable thymic tissue[ 146 ]. Thymus regeneration through tissue engineering: Decellularized thymic scaffolds repopulated with thymic epithelial cells and seeded with hematopoietic progenitors could provide bioengineered thymic grafts[ 147 ]. While this approach remains experimental, advances in tissue engineering and organoid technology may enable clinical translation.

Risk-benefit and pediatric safety considerations: Thymic restoration approaches are attractive in children because thymopoiesis is developmentally central to durable immune competence[ 148 ]; however, immune-augmenting strategies may also amplify alloreactivity[ 149 ]. In solid organ recipients, excessive immune reconstitution could precipitate rejection[ 150 ], and in HSCT recipients, it could exacerbate or trigger GVHD, particularly if immune recovery becomes uncoupled from tolerance[ 151 ]. In addition, growth hormone/IGF-1-based approaches require careful oncology-informed risk assessment given theoretical tumor-promoting concerns in a population already enriched for cancer susceptibility[ 152 , 153 ]. Accordingly, pediatric transplant applications should prioritize conservative dosing, real-time allograft/GVHD surveillance, and integration with immunosuppression adjustment algorithms rather than “immune boosting” in isolation[ 148 , 149 ].

Metabolic interventions

NAD+ precursors: NR and NMN restore NAD+ levels in preclinical models, improving mitochondrial function, enhancing DNA repair, activating SIRTs, and improving multiple aging hallmarks[ 154 ]. Human clinical trials demonstrate NR/NMN safety and NAD+ level restoration[ 155 ]. Whether NAD+ augmentation can improve immune function and mitigate accelerated aging in pediatric transplant recipients represents an important research question amenable to clinical trial testing.

Risk-benefit and pediatric safety considerations: Metabolic interventions ( e.g. , NAD+ augmentation, mitochondrial support, dietary modulation) are appealing because they may improve cellular resilience without directly reversing immune checkpoints[ 58 , 156 ]; however, pediatric transplant recipients have unique vulnerabilities related to growth, pubertal development, drug-drug interactions, and organ function[ 157 , 158 ]. Even when adult studies suggest tolerability, pediatric-specific pharmacology and long-term developmental outcomes are incompletely defined[ 159 , 160 ], and effects on immunosurveillance vs tolerance must be monitored to avoid destabilizing graft acceptance[ 161 , 162 ]. In practice, these approaches should be framed as adjunctive and biomarker-guided ( e.g. , tied to objective immunosenescence measures), with prospective monitoring for metabolic derangements, infection frequency, and any signal of altered rejection risk over time[ 158 ].

Mitochondrial-targeted antioxidants: Mitochondrial dysfunction and oxidative stress contribute to accelerated immune aging. Mitochondria-targeted antioxidants, including MitoQ (coenzyme Q10 conjugated to triphenylphosphonium cation) and SkQ1 (plastoquinone derivative), selectively accumulate in mitochondria, reducing oxidative damage[ 163 ]. Preclinical studies demonstrate beneficial effects on mitochondrial function, inflammation, and aging phenotypes[ 164 ]. Clinical trials in various conditions, including heart failure and metabolic syndrome, show promise[ 165 ].

Ketogenic diet and caloric restriction mimetics: Caloric restriction extends lifespan and healthspan across multiple species through mechanisms including mTOR inhibition, AMP-activated protein kinase activation, enhanced autophagy, improved mitochondrial function, and reduced inflammation[ 166 ]. Ketogenic diets and intermittent fasting regimens provide alternative approaches to achieve similar metabolic benefits without chronic caloric restriction[ 167 ]. In the transplant setting, dietary interventions represent relatively safe and accessible approaches that could potentially mitigate accelerated aging, though prospective trials with immune aging biomarker assessments are needed.

Checkpoint inhibitor modulation

Rationale and challenges: Immune checkpoint inhibitors (ICIs), antibodies blocking PD-1, programmed death ligand-1, or CTLA-4, revolutionized cancer treatment by reinvigorating exhausted T cells[ 164 ]. Given the central role of T cell exhaustion in accelerated immunosenescence and cancer predisposition in transplant recipients, ICIs represent an intellectually compelling therapeutic approach. However, ICIs carry a substantial risk of triggering allograft rejection through unleashing alloreactive T cells, creating a fundamental tension between cancer treatment and graft preservation[ 168 , 169 ].

Clinical experience with ICIs in transplant recipients: Kumar et al [ 170 ] systematically reviewed ICI use in solid organ transplant recipients, documenting substantial rejection risk (30%-40% across multiple case series) with variable outcomes depending on organ type, immunosuppression management, and ICI regimen. Liver transplant recipients demonstrated lower rejection rates compared to kidney recipients, possibly due to the liver’s tolerogenic properties[ 171 ]. Kayali et al [ 172 ] reported a pooled analysis of ICIs in liver transplant recipients showing an overall response rate of 29% with a rejection rate of 27%, suggesting therapeutic efficacy alongside significant risk.

Strategies to mitigate rejection risk while enabling ICI therapy include: (1) Maintaining baseline immunosuppression; (2) Using mTOR inhibitors that may synergize with ICIs while providing immunosuppression; (3) Local/regional ICI delivery to minimize systemic exposure; (4) Alternative checkpoint targeting (T-cell immunoglobulin and mucin domain-containing protein 3, lymphocyte-activation gene 3) with potentially lower rejection risk; and (5) Careful patient selection favoring those with life-threatening malignancies where benefits outweigh risks[ 173 ]. Pediatric-specific data remain extremely limited, necessitating case-by-case decision-making in multidisciplinary teams.

Risk-benefit and pediatric safety considerations: In immunosuppressed pediatric transplant recipients, PD-1/programmed death ligand-1 or CTLA-4 blockade represents one of the clearest examples of a high-stakes risk-benefit tradeoff: Potential anti-tumor benefit must be weighed against a clinically meaningful probability of acute allograft rejection[ 170 , 174 , 175 ]. Given that the evidence base in children is extremely limited[ 10 , 176 ], ICI use should be reserved for life-threatening malignancies with no reasonable alternatives and undertaken with multidisciplinary consensus[ 177 , 178 ]. Risk mitigation should be explicit in the therapeutic framing ( e.g. , maintaining baseline immunosuppression, considering mTOR-based regimens, and careful patient selection)[ 179 , 180 ], while counseling families that immune activation may be incompatible with durable graft preservation even with mitigation attempts[ 174 ].

Alternative approaches to reversing exhaustion: Beyond checkpoint inhibitors, alternative approaches to reverse T cell exhaustion include. Adoptive cell therapy: Ex vivo expansion and activation of tumor-specific T cells or CAR-T cells bypasses exhaustion of endogenous T cells[ 181 ]. Ligon et al [ 182 ] reviewed adoptive cell therapy in pediatric solid tumors, demonstrating feasibility and efficacy in selected malignancies. Adapting these approaches to transplant recipients with post-transplant malignancies while minimizing rejection risk represents an important frontier. Epigenetic reprogramming: Exhausted T cells exhibit epigenetic modifications stabilizing their dysfunctional state. Epigenetic modifiers, including DNA methyltransferase inhibitors and histone deacetylase inhibitors, can reverse some exhaustion features, potentially restoring anti-tumor immunity[ 183 ]. Clinical translation requires careful safety assessment. Metabolic reprogramming: Exhausted T cells demonstrate altered metabolism; metabolic interventions restoring glycolytic and mitochondrial function could reverse exhaustion[ 184 ]. Metformin, glutaminase inhibitors, and other metabolic modulators represent potential approaches.

CMV prevention and treatment optimization

Given CMV’s substantial contribution to accelerated immune aging, optimized CMV management represents a critical intervention: Prophylaxis vs preemptive therapy. Debate continues regarding optimal CMV management strategies. Universal prophylaxis prevents early CMV disease but delays immune priming, potentially increasing late CMV disease. Preemptive therapy (viral load monitoring with treatment of asymptomatic viremia) allows some immune priming while preventing disease[ 185 ]. Hybrid approaches tailored to immunosenescence risk may offer optimal outcomes. Letermovir: A novel anti-CMV agent with a distinct mechanism of action (viral terminase complex inhibition) offers improved tolerability compared to traditional agents (ganciclovir, valganciclovir). While currently approved only in HSCT recipients, extension to SOT recipients is under investigation. CMV-specific immunotherapy: Adoptive transfer of CMV-specific T cells generated from donors or third-party sources can restore CMV-specific immunity in high-risk recipients[ 186 ]. This approach directly addresses the immune deficit underlying CMV-driven immunosenescence. CMV vaccination: Vaccines preventing primary CMV infection in seronegative recipients or boosting immunity in seropositive recipients could substantially reduce CMV-driven immune aging[ 187 ]. Multiple vaccine candidates are in clinical development; successful vaccine development would represent a transformative advance in transplant medicine.

Risk-benefit and pediatric safety considerations: Because latent viral reactivation is both a driver of immune aging and a source of morbidity, CMV-directed strategies must balance near-term infection prevention with longer-term immune education and durability[ 21 , 184 ]. Universal prophylaxis may reduce early disease burden but could alter immune priming and shift risk to later reactivation[ 184 - 186 ], whereas preemptive approaches require reliable surveillance infrastructure and rapid treatment access to prevent progression[ 185 - 187 ]. In pediatric recipients, who may have more dynamic immune maturation and prolonged post-transplant life expectancy, strategy selection should explicitly consider cumulative antiviral exposure, adherence feasibility, and the downstream impact on broader herpesvirus control and malignancy risk[ 186 , 188 - 191 ].

Microbiome modulation

Emerging evidence links gut microbiome dysbiosis to systemic inflammation, immune dysfunction, and accelerated aging[ 192 ]. Transplant recipients demonstrate altered microbiome composition driven by antibiotics, immunosuppression, and dietary changes[ 193 - 199 ]. Microbiome-targeted interventions include: Probiotics and prebiotics. Specific bacterial strains ( Lactobacillus , Bifidobacterium ) and prebiotic fibers promoting beneficial bacteria may reduce inflammation and improve immune function[ 197 , 198 ]. Fecal microbiota transplantation (FMT): Transfer of a complete microbiome from healthy donors to recipients can restore microbiome diversity and function[ 199 ]. While primarily used for Clostridioides difficile infection, FMT is being explored for inflammatory and metabolic conditions; application to transplant recipients requires careful safety assessment. Dietary interventions: Mediterranean diet, high-fiber diet, and fermented foods promote beneficial microbiome composition and reduced inflammation[ 196 ].

Risk-benefit and pediatric safety considerations: Microbiome modulation is attractive because it may reduce systemic inflammation and improve immune tone[ 200 , 201 ]. However, in immunosuppressed children, the safety profile differs substantially from that of immunocompetent populations. Probiotics and diet are generally lower risk but still warrant caution in severely immunocompromised states[ 201 - 205 ], while FMT demands rigorous donor screening and transplant-specific safety protocols given the potential for transmission of pathogens or unintended immune effects. Therefore, microbiome interventions should be positioned as stepwise (diet/prebiotics/probiotics first, FMT only in selected indications) and ideally embedded in prospective studies that track infections, inflammation biomarkers, and graft outcomes[ 199 ].

TRANSLATING BIOMARKERS TO PRACTICE: RISK STRATIFICATION, SURVEILLANCE, AND CARE COORDINATION

Risk stratification and biomarker-driven care

Implementation of immunosenescence-focused care requires systematic risk stratification. Pre-transplant assessment: Baseline measurement of naive T cell populations, TREC levels, telomere length, inflammatory markers, and potentially epigenetic age establishes individualized risk profiles. Post-transplant monitoring: Serial assessments at standardized intervals (3 months, 6 months, 12 months, 24 months, then annually) track immune aging trajectories, identifying recipients with accelerated aging for intervention. Threshold-based interventions: Establishment of clinically validated thresholds for biomarkers triggers specific interventions ( e.g. , CD28-negative T cells > 60% prompts immunosuppression reduction consideration; TREC levels below threshold trigger thymic function enhancement strategies).

Cancer surveillance protocols

Enhanced cancer surveillance in high-risk recipients includes: (1) PTLD surveillance. Serial EBV viral load monitoring in high-risk recipients (EBV D+/R-, young age, high immunosuppression). Rising EBV viral loads trigger immunosuppression reduction and close monitoring; (2) Skin cancer screening. Annual dermatologic examination for all recipients; more frequent (every 3-6 months) for high-risk patients (fair skin, sun exposure). Patient education on self-examination and sun protection; (3) Colonoscopy. Earlier initiation and more frequent intervals compared to the general population, particularly in recipients with inflammatory bowel disease or other risk factors; and (4) HPV-related cancer screening. Age-appropriate cervical cancer screening; consideration of anal cancer screening in high-risk recipients. HPV vaccination pre- or early post-transplant.

Multidisciplinary care coordination

Optimal management requires coordination across specialties: (1) Transplant specialists. Immunosuppression management, rejection surveillance, and treatment; (2) Oncologists. Cancer risk assessment, surveillance protocol implementation, malignancy management. Infectious disease specialists: CMV and EBV management, prophylaxis optimization. Immunologists: Immune function assessment, interpretation of advanced immune monitoring; and (3) Geriatricians/geroscience specialists: Expertise in aging biology applicable to accelerated aging in pediatric recipients.

FUTURE RESEARCH DIRECTIONS

Prospective longitudinal cohort studies

Establishing comprehensive prospective cohorts with standardized biomarker assessments, clinical outcome tracking, and biospecimen banking is essential for: Validating immunosenescence biomarkers for cancer prediction; identifying modifiable risk factors for accelerated aging; enabling precision medicine approaches based on individual aging trajectories; and providing platforms for nested intervention trials.

Interventional clinical trials

Specific high-priority trials include: Senolytic therapy trial. Phase 2 randomized controlled trial of D + Q in transplant recipients with elevated senescence markers, with endpoints including senescent cell burden reduction, inflammatory marker changes, and immune function improvement. IL-7 immunotherapy trial: Dose-escalation and efficacy trial of recombinant IL-7 in recipients with low naive T cell counts and reduced thymic output, measuring TREC levels, T cell repertoire diversity, and rejection incidence. Metformin trial: Randomized trial of metformin vs placebo in non-diabetic transplant recipients, assessing inflammation, immune function, and cancer incidence. NAD+ augmentation trial: Trial of NR supplementation measuring NAD+ levels, mitochondrial function, immune parameters, and aging biomarkers.

Mechanistic studies

Deeper mechanistic understanding requires: Single-cell multi-omics. Single-cell RNA sequencing, TCR sequencing, and ATAC-seq defining transcriptional and epigenetic landscapes of aging immune cells in transplant recipients. Longitudinal epigenetic aging studies. Serial epigenetic clock measurements correlating biological age acceleration with clinical outcomes and immunosuppression exposure. Metabolomics and lipidomics. Comprehensive metabolic profiling identifying aging-associated metabolic signatures and potential therapeutic targets. Microbiome-immune interactions. Mechanistic studies linking gut microbiome composition to systemic inflammation and immune aging in transplant recipients.

Comparative effectiveness research

Systematic comparison of immunosuppressive regimens for their effects on immune aging: CNI vs mTOR inhibitor-based regimens. Head-to-head comparison with comprehensive immune aging biomarker assessment. ATG vs IL-2 receptor antagonist induction: Long-term immune aging outcomes comparing different induction strategies. Steroid minimization/withdrawal: Impact on inflammaging and immune aging trajectories.

Technology development

Point-of-care senescence assays. Development of rapid, accessible tests for senescence markers enabling real-time clinical decision-making. Artificial intelligence/machine learning models. Integration of multiple biomarkers, clinical variables, and genetic data to predict cancer risk and optimize immunosuppression. Wearable devices and digital health: Continuous monitoring of inflammation, physical function, and other aging-related parameters.

CONCLUSION

The emergence of accelerated immunosenescence as a central paradigm in pediatric transplant medicine fundamentally alters our understanding of post-transplant complications and long-term outcomes. The convergence of evidence demonstrating premature immune aging in pediatric recipients, mediated through ATG-induced T cell depletion, CMV reactivation, telomere dysfunction, thymic impairment, and inflammaging pathways, establishes a clear mechanistic framework linking transplantation-related interventions to cancer predisposition. This represents not merely an academic observation but an urgent clinical reality: Pediatric transplant recipients face cancer risks typically associated with individuals decades older, manifesting within years post-transplant and persisting throughout life.

The clinical implications extend far beyond immediate post-transplant management to encompass lifelong surveillance and intervention strategies. Recognition that immunosuppression inadvertently accelerates biological aging necessitates a comprehensive reconsideration of clinical approaches, emphasizing personalized, biomarker-driven immunosuppression strategies that account for individual immune aging trajectories while maintaining graft survival. The development of validated biomarker panels, integrating flow cytometric senescence markers, telomere length, inflammatory profiles, and potentially epigenetic clocks, enables risk stratification and targeted interventions in the highest-risk recipients.

Therapeutic horizons are expanding rapidly. Senolytic and senomorphic agents offer potential to eliminate or modulate senescent cells, driving inflammaging and immunosuppression. Thymic regeneration strategies, including IL-7 therapy, could restore immune competence through enhanced naive T cell generation. Metabolic interventions targeting NAD+ metabolism, mitochondrial function, and mTOR signaling may mitigate multiple aging hallmarks simultaneously. Careful application of checkpoint inhibitors in selected malignancies, optimized CMV prevention and treatment, and microbiome modulation represent additional therapeutic avenues. Each approach requires rigorous clinical trial evaluation with particular attention to safety in immunosuppressed pediatric populations.

The insights gained from studying accelerated immune aging in pediatric transplant recipients have broader implications extending beyond transplant medicine. This population represents a “natural experiment” in human aging, revealing mechanisms by which immune aging is accelerated and potentially providing insights into interventions applicable to physiological aging in the general population. The bidirectional translation of geroscience principles to transplant medicine and transplant-derived insights back to aging biology represents an exciting frontier with potential to benefit both transplant recipients and aging individuals generally.

Future research priorities are clear. Prospective longitudinal cohorts with comprehensive biomarker assessment and biospecimen banking; interventional trials of senolytics, immunomodulatory approaches, and metabolic interventions; mechanistic studies employing single-cell multi-omics technologies; and comparative effectiveness research systematically evaluating immunosuppressive regimens for their aging effects. These investigations will refine our understanding of accelerated aging mechanisms, validate biomarkers for clinical implementation, and establish evidence-based therapeutic strategies.

The ultimate goal is achieving optimal transplant outcomes while preserving immune competence sufficient for cancer surveillance and infection control, a paradigm shift toward precision medicine in pediatric transplantation that acknowledges the fundamental importance of immune aging in determining long-term success. Success in this endeavor requires sustained commitment from the transplant community, funding agencies, pharmaceutical industry, and regulatory bodies to prioritize aging biology in transplant research and clinical care. The vulnerable pediatric transplant population deserves no less than our comprehensive efforts to mitigate accelerated aging consequences and optimize their long-term health and quality of life.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

AI contribution statement: Grammarly and QuillBot were used for language refinement only. The scientific content was authored by the authors and was not AI-generated. Grammarly and QuillBot were used solely for language polishing and writing assistance to improve grammar and expression. They were not used for data analysis or translation. Study design, data interpretation, and all scientific judgments were performed entirely by the authors. No images in the manuscript were generated by AI.

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Pediatrics

Country of origin: Egypt

Peer-review report’s classification

Scientific quality: Grade B

Novelty: Grade B

Creativity or innovation: Grade B

Scientific significance: Grade B

P-Reviewer: Li Y, MD, China S-Editor: Wu S L-Editor: A P-Editor: Zheng XM

1 López-Otín C Blasco MA Partridge L Serrano M Kroemer G The hallmarks of aging Cell 2013 153 1194 1217 23746838 10.1016/j.cell.2013.05.039 PMC3836174

2 McGovern KE Sonar SA Watanabe M Coplen CP Bradshaw CM Nikolich JŽ The aging of the immune system and its implications for transplantation Geroscience 2023 45 1383 1400 36626019 10.1007/s11357-022-00720-2 PMC9838392

3 Krenzien F ElKhal A Quante M Rodriguez Cetina Biefer H Hirofumi U Gabardi S Tullius SG A Rationale for Age-Adapted Immunosuppression in Organ Transplantation Transplantation 2015 99 2258 2268 26244716 10.1097/TP.0000000000000842 PMC4618718

4 Singh A Schurman SH Bektas A Kaileh M Roy R Wilson DM 3rd Sen R Ferrucci L Aging and Inflammation Cold Spring Harb Perspect Med 2024 14 a041197 38052484 10.1101/cshperspect.a041197 PMC11146314

5 Coppé JP Desprez PY Krtolica A Campisi J The senescence-associated secretory phenotype: the dark side of tumor suppression Annu Rev Pathol 2010 5 99 118 20078217 10.1146/annurev-pathol-121808-102144 PMC4166495

6 Kapse B Budev MM Singer JP Greenland JR Immune aging: biological mechanisms, clinical symptoms, and management in lung transplant recipients Front Transplant 2024 3 1356948 38993782 10.3389/frtra.2024.1356948 PMC11235310

7 Yanik EL Smith JM Shiels MS Clarke CA Lynch CF Kahn AR Koch L Pawlish KS Engels EA Cancer Risk After Pediatric Solid Organ Transplantation Pediatrics 2017 139 e20163893 28557749 10.1542/peds.2016-3893 PMC5404730

8 Kitchlu A Dixon S Dirk JS Chanchlani R Vasilevska-Ristovska J Borges K Dipchand AI Ng VL Hebert D Solomon M Michael Paterson J Gupta S Joseph Kim S Nathan PC Parekh RS Elevated Risk of Cancer After Solid Organ Transplant in Childhood: A Population-based Cohort Study Transplantation 2019 103 588 596 30048393 10.1097/TP.0000000000002378

9 Nordin A Åberg F Pukkala E Pedersen CR Storm HH Rasmussen A Bennet W Olausson M Wilczek H Ericzon BG Tretli S Line PD Karlsen TH Boberg KM Isoniemi H Decreasing incidence of cancer after liver transplantation-A Nordic population-based study over 3 decades Am J Transplant 2018 18 952 963 28925583 10.1111/ajt.14507

10 Endén K Tainio J Nikkilä A Helanterä I Nordin A Pakarinen MP Jalanko H Jahnukainen K Jahnukainen T Cancer morbidity and mortality after pediatric solid organ transplantation-a nationwide register study Pediatr Nephrol 2020 35 1719 1728 32394187 10.1007/s00467-020-04546-y PMC7385020

11 Ploos van Amstel S Vogelzang JL Starink MV Jager KJ Groothoff JW Long-Term Risk of Cancer in Survivors of Pediatric ESRD Clin J Am Soc Nephrol 2015 10 2198 2204 26430089 10.2215/CJN.03630415 PMC4670765

12 Kahn JM Brazauskas R Tecca HR Bo-Subait S Buchbinder D Battiwala M Flowers MED Savani BN Phelan R Broglie L Abraham AA Keating AK Daly A Wirk B George B Alter BP Ustun C Freytes CO Beitinjaneh AM Duncan C Copelan E Hildebrandt GC Murthy HS Lazarus HM Auletta JJ Myers KC Williams KM Page KM Vrooman LM Norkin M Byrne M Diaz MA Kamani N Bhatt NS Rezvani A Farhadfar N Mehta PA Hematti P Shaw PJ Kamble RT Schears R Olsson RF Hayashi RJ Gale RP Mayo SJ Chhabra S Rotz SJ Badawy SM Ganguly S Pavletic S Nishihori T Prestidge T Agrawal V Hogan WJ Inamoto Y Shaw BE Satwani P Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases Blood Adv 2020 4 2084 2094 32396620 10.1182/bloodadvances.2019000839 PMC7218429

13 Bomken S Skinner R Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in Childhood Children (Basel) 2015 2 146 173 27417356 10.3390/children2020146 PMC4928755

14 Bosch M Dhadda M Hoegh-Petersen M Liu Y Hagel LM Podgorny P Ugarte-Torres A Khan FM Luider J Auer-Grzesiak I Mansoor A Russell JA Daly A Stewart DA Maloney D Boeckh M Storek J Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation Cytotherapy 2012 14 1258 1275 22985195 10.3109/14653249.2012.715243 PMC3681879

15 Crepin T Carron C Roubiou C Gaugler B Gaiffe E Simula-Faivre D Ferrand C Tiberghien P Chalopin JM Moulin B Frimat L Rieu P Saas P Ducloux D Bamoulid J ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients Am J Transplant 2015 15 1028 1038 25758660 10.1111/ajt.13092

16 Servais S Menten-Dedoyart C Beguin Y Seidel L Gothot A Daulne C Willems E Delens L Humblet-Baron S Hannon M Baron F Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation PLoS One 2015 10 e0130026 26098781 10.1371/journal.pone.0130026 PMC4476691

17 Xia CQ Chernatynskaya AV Wasserfall CH Wan S Looney BM Eisenbeis S Williams J Clare-Salzler MJ Atkinson MA Anti-thymocyte globulin (ATG) differentially depletes naïve and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice BMC Immunol 2012 13 70 23237483 10.1186/1471-2172-13-70 PMC3547787

18 Lee GH Lee JY Jang J Kang YJ Choi SA Kim HC Park S Kim MS Lee WW Anti-thymocyte globulin-mediated immunosenescent alterations of T cells in kidney transplant patients Clin Transl Immunology 2022 11 e1431 36439636 10.1002/cti2.1431 PMC9686013

19 Higdon LE Gustafson CE Ji X Sahoo MK Pinsky BA Margulies KB Maecker HT Goronzy J Maltzman JS Association of Premature Immune Aging and Cytomegalovirus After Solid Organ Transplant Front Immunol 2021 12 661551 34122420 10.3389/fimmu.2021.661551 PMC8190404

20 Blackburn EH Epel ES Lin J Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection Science 2015 350 1193 1198 26785477 10.1126/science.aab3389

21 Semmes EC Hurst JH Walsh KM Permar SR Cytomegalovirus as an immunomodulator across the lifespan Curr Opin Virol 2020 44 112 120 32818717 10.1016/j.coviro.2020.07.013 PMC7755826

22 Jackson SE Noor M Lim E Wills M The immune response to human cytomegalovirus: impact of age, co-morbidities and the significance of anti-viral activity assessment Philos Trans R Soc Lond B Biol Sci 2025 380 20240408 41194662 10.1098/rstb.2024.0408 PMC12590175

23 Müller L Di Benedetto S Immunosenescence and Cytomegalovirus: Exploring Their Connection in the Context of Aging, Health, and Disease Int J Mol Sci 2024 25 753 38255826 10.3390/ijms25020753 PMC10815036

24 d'Adda di Fagagna F Reaper PM Clay-Farrace L Fiegler H Carr P Von Zglinicki T Saretzki G Carter NP Jackson SP A DNA damage checkpoint response in telomere-initiated senescence Nature 2003 426 194 198 14608368 10.1038/nature02118

25 Coppé JP Patil CK Rodier F Sun Y Muñoz DP Goldstein J Nelson PS Desprez PY Campisi J Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor PLoS Biol 2008 6 2853 2868 19053174 10.1371/journal.pbio.0060301 PMC2592359

26 Wang Y McReynolds LJ Dagnall C Katki HA Spellman SR Wang T Hicks B Freedman ND Jones K Lee SJ Savage SA Gadalla SM Pre-transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia Br J Haematol 2020 188 309 316 31426123 10.1111/bjh.16153 PMC6980174

27 Song N Li Z Qin N Howell CR Wilson CL Easton J Mulder HL Edmonson MN Rusch MC Zhang J Hudson MM Yasui Y Robison LL Ness KK Wang Z Shortened Leukocyte Telomere Length Associates with an Increased Prevalence of Chronic Health Conditions among Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Clin Cancer Res 2020 26 2362 2371 31969337 10.1158/1078-0432.CCR-19-2503 PMC7231652

28 Zhang C Ostrom QT Semmes EC Ramaswamy V Hansen HM Morimoto L de Smith AJ Pekmezci M Vaksman Z Hakonarson H Diskin SJ Metayer C Glioma International Case-Control Study (GICC), Taylor MD, Wiemels JL, Bondy ML, Walsh KM Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma Acta Neuropathol Commun 2020 8 173 33115534 10.1186/s40478-020-01038-w PMC7592366

29 Takaba H Takayanagi H The Mechanisms of T Cell Selection in the Thymus Trends Immunol 2017 38 805 816 28830733 10.1016/j.it.2017.07.010

30 Douek DC McFarland RD Keiser PH Gage EA Massey JM Haynes BF Polis MA Haase AT Feinberg MB Sullivan JL Jamieson BD Zack JA Picker LJ Koup RA Changes in thymic function with age and during the treatment of HIV infection Nature 1998 396 690 695 9872319 10.1038/25374

31 Lynch HE Goldberg GL Chidgey A Van den Brink MR Boyd R Sempowski GD Thymic involution and immune reconstitution Trends Immunol 2009 30 366 373 19540807 10.1016/j.it.2009.04.003 PMC2750859

32 Junge S Kloeckener-Gruissem B Zufferey R Keisker A Salgo B Fauchere JC Scherer F Shalaby T Grotzer M Siler U Seger R Güngör T Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4+ T cells in normal individuals during aging and in lymphopenic children Eur J Immunol 2007 37 3270 3280 17935071 10.1002/eji.200636976

33 Levy A Rangel-Santos A Torres LC Silveira-Abreu G Agena F Carneiro-Sampaio M T cell receptor excision circles as a tool for evaluating thymic function in young children Braz J Med Biol Res 2019 52 e8292 31241713 10.1590/1414-431X20198292 PMC6596370

34 Mengrelis K Kucera F Shahid N Watt E Ross S Lau CI Adams S Gilmour K Pils D Crompton T Burch M Davies EG T cell phenotype in paediatric heart transplant recipients Pediatr Transplant 2021 25 e13930 33326675 10.1111/petr.13930

35 Gaballa A Clave E Uhlin M Toubert A Arruda LCM Evaluating Thymic Function After Human Hematopoietic Stem Cell Transplantation in the Personalized Medicine Era Front Immunol 2020 11 1341 32849495 10.3389/fimmu.2020.01341 PMC7412601

36 Williams KM Hakim FT Gress RE T cell immune reconstitution following lymphodepletion Semin Immunol 2007 19 318 330 18023361 10.1016/j.smim.2007.10.004 PMC2180244

37 Mackall CL Punt JA Morgan P Farr AG Gress RE Thymic function in young/old chimeras: substantial thymic T cell regenerative capacity despite irreversible age-associated thymic involution Eur J Immunol 1998 28 1886 1893 9645370 10.1002/(SICI)1521-4141(199806)28:06<1886::AID-IMMU1886>3.0.CO;2-M

38 Kanakry CG Coffey DG Towlerton AM Vulic A Storer BE Chou J Yeung CC Gocke CD Robins HS O'Donnell PV Luznik L Warren EH Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide JCI Insight 2016 1 e86252 27213183 10.1172/jci.insight.86252 PMC4874509

39 Ciupe SM Devlin BH Markert ML Kepler TB The dynamics of T-cell receptor repertoire diversity following thymus transplantation for DiGeorge anomaly PLoS Comput Biol 2009 5 e1000396 19521511 10.1371/journal.pcbi.1000396 PMC2690399

40 Franceschi C Bonafè M Valensin S Olivieri F De Luca M Ottaviani E De Benedictis G Inflamm-aging. An evolutionary perspective on immunosenescence Ann N Y Acad Sci 2000 908 244 254 10911963 10.1111/j.1749-6632.2000.tb06651.x

41 Ferrucci L Fabbri E Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty Nat Rev Cardiol 2018 15 505 522 30065258 10.1038/s41569-018-0064-2 PMC6146930

42 Franzin R Stasi A Fiorentino M Stallone G Cantaluppi V Gesualdo L Castellano G Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage Front Immunol 2020 11 734 32457738 10.3389/fimmu.2020.00734 PMC7221190

43 Takasugi M Yoshida Y Ohtani N Cellular senescence and the tumour microenvironment Mol Oncol 2022 16 3333 3351 35674109 10.1002/1878-0261.13268 PMC9490140

44 Coppé JP Patil CK Rodier F Krtolica A Beauséjour CM Parrinello S Hodgson JG Chin K Desprez PY Campisi J A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen PLoS One 2010 5 e9188 20169192 10.1371/journal.pone.0009188 PMC2820538

45 Solana R Tarazona R Aiello AE Akbar AN Appay V Beswick M Bosch JA Campos C Cantisán S Cicin-Sain L Derhovanessian E Ferrando-Martínez S Frasca D Fulöp T Govind S Grubeck-Loebenstein B Hill A Hurme M Kern F Larbi A López-Botet M Maier AB McElhaney JE Moss P Naumova E Nikolich-Zugich J Pera A Rector JL Riddell N Sanchez-Correa B Sansoni P Sauce D van Lier R Wang GC Wills MR Zieliński M Pawelec G CMV and Immunosenescence: from basics to clinics Immun Ageing 2012 9 23 23114110 10.1186/1742-4933-9-23 PMC3585851

46 Molony RD Nguyen JT Kong Y Montgomery RR Shaw AC Iwasaki A Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes Sci Signal 2017 10 eaan2392 29233916 10.1126/scisignal.aan2392 PMC6429941

47 Sapey E Greenwood H Walton G Mann E Love A Aaronson N Insall RH Stockley RA Lord JM Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence Blood 2014 123 239 248 24191150 10.1182/blood-2013-08-519520 PMC3888290

48 Johnson SC Rabinovitch PS Kaeberlein M mTOR is a key modulator of ageing and age-related disease Nature 2013 493 338 345 23325216 10.1038/nature11861 PMC3687363

49 Saxton RA Sabatini DM mTOR Signaling in Growth, Metabolism, and Disease Cell 2017 168 960 976 28283069 10.1016/j.cell.2017.02.004 PMC5394987

50 Pollizzi KN Powell JD Integrating canonical and metabolic signalling programmes in the regulation of T cell responses Nat Rev Immunol 2014 14 435 446 24962260 10.1038/nri3701 PMC4390057

51 Blagosklonny MV Rapamycin extends life- and health span because it slows aging Aging (Albany NY) 2013 5 592 598 23934728 10.18632/aging.100591 PMC3796212

52 Di Francesco A Di Germanio C Bernier M de Cabo R A time to fast Science 2018 362 770 775 30442801 10.1126/science.aau2095 PMC8504313

53 Sun N Youle RJ Finkel T The Mitochondrial Basis of Aging Mol Cell 2016 61 654 666 26942670 10.1016/j.molcel.2016.01.028 PMC4779179

54 Baixauli F Acín-Pérez R Villarroya-Beltrí C Mazzeo C Nuñez-Andrade N Gabandé-Rodriguez E Ledesma MD Blázquez A Martin MA Falcón-Pérez JM Redondo JM Enríquez JA Mittelbrunn M Mitochondrial Respiration Controls Lysosomal Function during Inflammatory T Cell Responses Cell Metab 2015 22 485 498 26299452 10.1016/j.cmet.2015.07.020 PMC5026297

55 Linares JF Cordes T Duran A Reina-Campos M Valencia T Ahn CS Castilla EA Moscat J Metallo CM Diaz-Meco MT ATF4-Induced Metabolic Reprograming Is a Synthetic Vulnerability of the p62-Deficient Tumor Stroma Cell Metab 2017 26 817 829.e6 28988820 10.1016/j.cmet.2017.09.001 PMC5718961

56 Schieber M Chandel NS ROS function in redox signaling and oxidative stress Curr Biol 2014 24 R453 R462 24845678 10.1016/j.cub.2014.03.034 PMC4055301

57 Passos JF Saretzki G Ahmed S Nelson G Richter T Peters H Wappler I Birket MJ Harold G Schaeuble K Birch-Machin MA Kirkwood TB von Zglinicki T Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence PLoS Biol 2007 5 e110 17472436 10.1371/journal.pbio.0050110 PMC1858712

58 Imai S Guarente L NAD+ and sirtuins in aging and disease Trends Cell Biol 2014 24 464 471 24786309 10.1016/j.tcb.2014.04.002 PMC4112140

59 Gomes AP Price NL Ling AJ Moslehi JJ Montgomery MK Rajman L White JP Teodoro JS Wrann CD Hubbard BP Mercken EM Palmeira CM de Cabo R Rolo AP Turner N Bell EL Sinclair DA Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging Cell 2013 155 1624 1638 24360282 10.1016/j.cell.2013.11.037 PMC4076149

60 Cheng HL Mostoslavsky R Saito S Manis JP Gu Y Patel P Bronson R Appella E Alt FW Chua KF Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice Proc Natl Acad Sci U S A 2003 100 10794 10799 12960381 10.1073/pnas.1934713100 PMC196882

61 Zhang H Ryu D Wu Y Gariani K Wang X Luan P D'Amico D Ropelle ER Lutolf MP Aebersold R Schoonjans K Menzies KJ Auwerx J NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice Science 2016 352 1436 1443 27127236 10.1126/science.aaf2693

62 Horvath S DNA methylation age of human tissues and cell types Genome Biol 2013 14 R115 24138928 10.1186/gb-2013-14-10-r115 PMC4015143

63 Horvath S Raj K DNA methylation-based biomarkers and the epigenetic clock theory of ageing Nat Rev Genet 2018 19 371 384 29643443 10.1038/s41576-018-0004-3

64 Quach A Levine ME Tanaka T Lu AT Chen BH Ferrucci L Ritz B Bandinelli S Neuhouser ML Beasley JM Snetselaar L Wallace RB Tsao PS Absher D Assimes TL Stewart JD Li Y Hou L Baccarelli AA Whitsel EA Horvath S Epigenetic clock analysis of diet, exercise, education, and lifestyle factors Aging (Albany NY) 2017 9 419 446 28198702 10.18632/aging.101168 PMC5361673

65 Sen P Shah PP Nativio R Berger SL Epigenetic Mechanisms of Longevity and Aging Cell 2016 166 822 839 27518561 10.1016/j.cell.2016.07.050 PMC5821249

66 Hannum G Guinney J Zhao L Zhang L Hughes G Sadda S Klotzle B Bibikova M Fan JB Gao Y Deconde R Chen M Rajapakse I Friend S Ideker T Zhang K Genome-wide methylation profiles reveal quantitative views of human aging rates Mol Cell 2013 49 359 367 23177740 10.1016/j.molcel.2012.10.016 PMC3780611

67 Levine ME Lu AT Quach A Chen BH Assimes TL Bandinelli S Hou L Baccarelli AA Stewart JD Li Y Whitsel EA Wilson JG Reiner AP Aviv A Lohman K Liu Y Ferrucci L Horvath S An epigenetic biomarker of aging for lifespan and healthspan Aging (Albany NY) 2018 10 573 591 29676998 10.18632/aging.101414 PMC5940111

68 Engels EA Pfeiffer RM Fraumeni JF Jr Kasiske BL Israni AK Snyder JJ Wolfe RA Goodrich NP Bayakly AR Clarke CA Copeland G Finch JL Fleissner ML Goodman MT Kahn A Koch L Lynch CF Madeleine MM Pawlish K Rao C Williams MA Castenson D Curry M Parsons R Fant G Lin M Spectrum of cancer risk among US solid organ transplant recipients JAMA 2011 306 1891 1901 22045767 10.1001/jama.2011.1592 PMC3310893

69 Dunn GP Old LJ Schreiber RD The three Es of cancer immunoediting Annu Rev Immunol 2004 22 329 360 15032581 10.1146/annurev.immunol.22.012703.104803

70 Schreiber RD Old LJ Smyth MJ Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 2011 331 1565 1570 21436444 10.1126/science.1203486

71 Das RK Vernau L Grupp SA Barrett DM Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers Cancer Discov 2019 9 492 499 30630850 10.1158/2159-8290.CD-18-1314 PMC6676489

72 Bailur JK McCachren SS Pendleton K Vasquez JC Lim HS Duffy A Doxie DB Kaushal A Foster C DeRyckere D Castellino S Kemp ML Qiu P Dhodapkar MV Dhodapkar KM Risk-associated alterations in marrow T cells in pediatric leukemia JCI Insight 2020 5 e140179 32692727 10.1172/jci.insight.140179 PMC7455136

73 Cawthon RM Telomere measurement by quantitative PCR Nucleic Acids Res 2002 30 e47 12000852 10.1093/nar/30.10.e47 PMC115301

74 Tancredi S Cullati S Chiolero A Screening and Surveillance Bias in Cancer Epidemiologia (Basel) 2023 4 117 120 37092457 10.3390/epidemiologia4020012 PMC10123698

75 Ahmed S Silverberg MJ Engels EA Pretransplant screening and lower incidence of breast and prostate cancers among organ transplant recipients in the United States JNCI Cancer Spectr 2025 9 pkaf080 40795156 10.1093/jncics/pkaf080 PMC12409407

76 Tajima T Martinez OM Bernstein D Boyd SD Gratzinger D Lum G Sasaki K Tan B Twist CJ Weinberg K Armstrong B Desai DM Mazariegos GV Chin C Fishbein TM Tekin A Venick RS Krams SM Esquivel CO Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States Pediatr Transplant 2024 28 e14763 38682750 10.1111/petr.14763 PMC11115376

77 Petrara MR Shalaby S Ruffoni E Taborelli M Carmona F Giunco S Del Bianco P Piselli P Serraino D Cillo U Dolcetti R Burra P De Rossi A Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients Front Oncol 2022 12 899170 35769714 10.3389/fonc.2022.899170 PMC9235349

78 Rich NE Parikh ND Singal AG Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance Semin Liver Dis 2017 37 296 304 29272892 10.1055/s-0037-1608775 PMC8136685

79 Angeletti A Cantarelli C Riella LV Fribourg M Cravedi P T-cell Exhaustion in Organ Transplantation Transplantation 2022 106 489 499 34115657 10.1097/TP.0000000000003851

80 Macián F López-Rodríguez C Rao A Partners in transcription: NFAT and AP-1 Oncogene 2001 20 2476 2489 11402342 10.1038/sj.onc.1204386

81 Wherry EJ Kurachi M Molecular and cellular insights into T cell exhaustion Nat Rev Immunol 2015 15 486 499 26205583 10.1038/nri3862 PMC4889009

82 Shahbazi M Soltanzadeh-Yamchi M Mohammadnia-Afrouzi M T cell exhaustion implications during transplantation Immunol Lett 2018 202 52 58 30130559 10.1016/j.imlet.2018.08.003

83 Alfei F Kanev K Hofmann M Wu M Ghoneim HE Roelli P Utzschneider DT von Hoesslin M Cullen JG Fan Y Eisenberg V Wohlleber D Steiger K Merkler D Delorenzi M Knolle PA Cohen CJ Thimme R Youngblood B Zehn D TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection Nature 2019 571 265 269 31207605 10.1038/s41586-019-1326-9

84 Pauken KE Sammons MA Odorizzi PM Manne S Godec J Khan O Drake AM Chen Z Sen DR Kurachi M Barnitz RA Bartman C Bengsch B Huang AC Schenkel JM Vahedi G Haining WN Berger SL Wherry EJ Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade Science 2016 354 1160 1165 27789795 10.1126/science.aaf2807 PMC5484795

85 Allen UD Farkas G Hébert D Weitzman S Stephens D Petric M Tellier R Ngan B Fecteau A West L Wasfy S Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study Pediatr Transplant 2005 9 450 455 16048596 10.1111/j.1399-3046.2005.00318.x

86 Fulchiero R Amaral S Post-transplant lymphoproliferative disease after pediatric kidney transplant Front Pediatr 2022 10 1087864 36568415 10.3389/fped.2022.1087864 PMC9768432

87 Young LS Yap LF Murray PG Epstein-Barr virus: more than 50 years old and still providing surprises Nat Rev Cancer 2016 16 789 802 27687982 10.1038/nrc.2016.92

88 Jia L Yang H Zhou Y Meng Y Zhang L Lei X Guan X Yu J Dou Y Analysis of risk factors for Epstein-Barr virus reactivation and progression to post-transplant lymphoproliferative disorder in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation Front Pediatr 2025 13 1627990 40746349 10.3389/fped.2025.1627990 PMC12310745

89 Green M Michaels MG Webber SA Rowe D Reyes J The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients Pediatr Transplant 1999 3 271 281 10562971 10.1034/j.1399-3046.1999.00066.x

90 Seyed-Khorami SM Azadi A Habibian A Hosseini M Fan X Soleimanjahi H Pourkarim MR Oncogenic Viruses in Organ Transplantation: Implications of Virus-Host Interactions for Cancer Development Viruses 2025 17 1299 41157571 10.3390/v17101299 PMC12567568

91 Gabrilovich DI Ostrand-Rosenberg S Bronte V Coordinated regulation of myeloid cells by tumours Nat Rev Immunol 2012 12 253 268 22437938 10.1038/nri3175 PMC3587148

92 Campisi J Aging, cellular senescence, and cancer Annu Rev Physiol 2013 75 685 705 23140366 10.1146/annurev-physiol-030212-183653 PMC4166529

93 Kuilman T Michaloglou C Vredeveld LC Douma S van Doorn R Desmet CJ Aarden LA Mooi WJ Peeper DS Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network Cell 2008 133 1019 1031 18555778 10.1016/j.cell.2008.03.039

94 Egeblad M Werb Z New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2002 2 161 174 11990853 10.1038/nrc745

95 Vallejo AN CD28 extinction in human T cells: altered functions and the program of T-cell senescence Immunol Rev 2005 205 158 169 15882352 10.1111/j.0105-2896.2005.00256.x

96 Schaenman JM Rossetti M Sidwell T Groysberg V Sunga G Korin Y Liang E Zhou X Abdalla B Lum E Bunnapradist S Pham T Danovitch G Reed EF Increased T cell immunosenescence and accelerated maturation phenotypes in older kidney transplant recipients Hum Immunol 2018 79 659 667 29913200 10.1016/j.humimm.2018.06.006 PMC6429965

97 Dedeoglu B Meijers RW Klepper M Hesselink DA Baan CC Litjens NH Betjes MG Loss of CD28 on Peripheral T Cells Decreases the Risk for Early Acute Rejection after Kidney Transplantation PLoS One 2016 11 e0150826 26950734 10.1371/journal.pone.0150826 PMC4780739

98 Voehringer D Koschella M Pircher H Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1) Blood 2002 100 3698 3702 12393723 10.1182/blood-2002-02-0657

99 Brenchley JM Karandikar NJ Betts MR Ambrozak DR Hill BJ Crotty LE Casazza JP Kuruppu J Migueles SA Connors M Roederer M Douek DC Koup RA Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells Blood 2003 101 2711 2720 12433688 10.1182/blood-2002-07-2103

100 Sallusto F Lenig D Förster R Lipp M Lanzavecchia A Two subsets of memory T lymphocytes with distinct homing potentials and effector functions Nature 1999 401 708 712 10537110 10.1038/44385

101 Kohler S Thiel A Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets Blood 2009 113 769 774 18583570 10.1182/blood-2008-02-139154

102 Hazenberg MD Verschuren MC Hamann D Miedema F van Dongen JJ T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation J Mol Med (Berl) 2001 79 631 640 11715066 10.1007/s001090100271

103 Baerlocher GM Vulto I de Jong G Lansdorp PM Flow cytometry and FISH to measure the average length of telomeres (flow FISH) Nat Protoc 2006 1 2365 2376 17406480 10.1038/nprot.2006.263

104 Kimura M Stone RC Hunt SC Skurnick J Lu X Cao X Harley CB Aviv A Measurement of telomere length by the Southern blot analysis of terminal restriction fragment lengths Nat Protoc 2010 5 1596 1607 21085125 10.1038/nprot.2010.124

105 Ferrucci L Corsi A Lauretani F Bandinelli S Bartali B Taub DD Guralnik JM Longo DL The origins of age-related proinflammatory state Blood 2005 105 2294 2299 15572589 10.1182/blood-2004-07-2599 PMC9828256

106 Axelsson J Møller HJ Witasp A Qureshi AR Carrero JJ Heimbürger O Bárány P Alvestrand A Lindholm B Moestrup SK Stenvinkel P Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD Am J Kidney Dis 2006 48 916 925 17162146 10.1053/j.ajkd.2006.08.022

107 Lu AT Quach A Wilson JG Reiner AP Aviv A Raj K Hou L Baccarelli AA Li Y Stewart JD Whitsel EA Assimes TL Ferrucci L Horvath S DNA methylation GrimAge strongly predicts lifespan and healthspan Aging (Albany NY) 2019 11 303 327 30669119 10.18632/aging.101684 PMC6366976

108 Cossarizza A Chang HD Radbruch A Acs A Adam D Adam-Klages S Agace WW Aghaeepour N Akdis M Allez M Almeida LN Alvisi G Anderson G Andrä I Annunziato F Anselmo A Bacher P Baldari CT Bari S Barnaba V Barros-Martins J Battistini L Bauer W Baumgart S Baumgarth N Baumjohann D Baying B Bebawy M Becher B Beisker W Benes V Beyaert R Blanco A Boardman DA Bogdan C Borger JG Borsellino G Boulais PE Bradford JA Brenner D Brinkman RR Brooks AES Busch DH Büscher M Bushnell TP Calzetti F Cameron G Cammarata I Cao X Cardell SL Casola S Cassatella MA Cavani A Celada A Chatenoud L Chattopadhyay PK Chow S Christakou E Čičin-Šain L Clerici M Colombo FS Cook L Cooke A Cooper AM Corbett AJ Cosma A Cosmi L Coulie PG Cumano A Cvetkovic L Dang VD Dang-Heine C Davey MS Davies D De Biasi S Del Zotto G Dela Cruz GV Delacher M Della Bella S Dellabona P Deniz G Dessing M Di Santo JP Diefenbach A Dieli F Dolf A Dörner T Dress RJ Dudziak D Dustin M Dutertre CA Ebner F Eckle SBG Edinger M Eede P Ehrhardt GRA Eich M Engel P Engelhardt B Erdei A Esser C Everts B Evrard M Falk CS Fehniger TA Felipo-Benavent M Ferry H Feuerer M Filby A Filkor K Fillatreau S Follo M Förster I Foster J Foulds GA Frehse B Frenette PS Frischbutter S Fritzsche W Galbraith DW Gangaev A Garbi N Gaudilliere B Gazzinelli RT Geginat J Gerner W Gherardin NA Ghoreschi K Gibellini L Ginhoux F Goda K Godfrey DI Goettlinger C González-Navajas JM Goodyear CS Gori A Grogan JL Grummitt D Grützkau A Haftmann C Hahn J Hammad H Hämmerling G Hansmann L Hansson G Harpur CM Hartmann S Hauser A Hauser AE Haviland DL Hedley D Hernández DC Herrera G Herrmann M Hess C Höfer T Hoffmann P Hogquist K Holland T Höllt T Holmdahl R Hombrink P Houston JP Hoyer BF Huang B Huang FP Huber JE Huehn J Hundemer M Hunter CA Hwang WYK Iannone A Ingelfinger F Ivison SM Jäck HM Jani PK Jávega B Jonjic S Kaiser T Kalina T Kamradt T Kaufmann SHE Keller B Ketelaars SLC Khalilnezhad A Khan S Kisielow J Klenerman P Knopf J Koay HF Kobow K Kolls JK Kong WT Kopf M Korn T Kriegsmann K Kristyanto H Kroneis T Krueger A Kühne J Kukat C Kunkel D Kunze-Schumacher H Kurosaki T Kurts C Kvistborg P Kwok I Landry J Lantz O Lanuti P LaRosa F Lehuen A LeibundGut-Landmann S Leipold MD Leung LYT Levings MK Lino AC Liotta F Litwin V Liu Y Ljunggren HG Lohoff M Lombardi G Lopez L López-Botet M Lovett-Racke AE Lubberts E Luche H Ludewig B Lugli E Lunemann S Maecker HT Maggi L Maguire O Mair F Mair KH Mantovani A Manz RA Marshall AJ Martínez-Romero A Martrus G Marventano I Maslinski W Matarese G Mattioli AV Maueröder C Mazzoni A McCluskey J McGrath M McGuire HM McInnes IB Mei HE Melchers F Melzer S Mielenz D Miller SD Mills KHG Minderman H Mjösberg J Moore J Moran B Moretta L Mosmann TR Müller S Multhoff G Muñoz LE Münz C Nakayama T Nasi M Neumann K Ng LG Niedobitek A Nourshargh S Núñez G O'Connor JE Ochel A Oja A Ordonez D Orfao A Orlowski-Oliver E Ouyang W Oxenius A Palankar R Panse I Pattanapanyasat K Paulsen M Pavlinic D Penter L Peterson P Peth C Petriz J Piancone F Pickl WF Piconese S Pinti M Pockley AG Podolska MJ Poon Z Pracht K Prinz I Pucillo CEM Quataert SA Quatrini L Quinn KM Radbruch H Radstake TRDJ Rahmig S Rahn HP Rajwa B Ravichandran G Raz Y Rebhahn JA Recktenwald D Reimer D Reis e Sousa C Remmerswaal EBM Richter L Rico LG Riddell A Rieger AM Robinson JP Romagnani C Rubartelli A Ruland J Saalmüller A Saeys Y Saito T Sakaguchi S Sala-de-Oyanguren F Samstag Y Sanderson S Sandrock I Santoni A Sanz RB Saresella M Sautes-Fridman C Sawitzki B Schadt L Scheffold A Scherer HU Schiemann M Schildberg FA Schimisky E Schlitzer A Schlosser J Schmid S Schmitt S Schober K Schraivogel D Schuh W Schüler T Schulte R Schulz AR Schulz SR Scottá C Scott-Algara D Sester DP Shankey TV Silva-Santos B Simon AK Sitnik KM Sozzani S Speiser DE Spidlen J Stahlberg A Stall AM Stanley N Stark R Stehle C Steinmetz T Stockinger H Takahama Y Takeda K Tan L Tárnok A Tiegs G Toldi G Tornack J Traggiai E Trebak M Tree TIM Trotter J Trowsdale J Tsoumakidou M Ulrich H Urbanczyk S van de Veen W van den Broek M van der Pol E Van Gassen S Van Isterdael G van Lier RAW Veldhoen M Vento-Asturias S Vieira P Voehringer D Volk HD von Borstel A von Volkmann K Waisman A Walker RV Wallace PK Wang SA Wang XM Ward MD Ward-Hartstonge KA Warnatz K Warnes G Warth S Waskow C Watson JV Watzl C Wegener L Weisenburger T Wiedemann A Wienands J Wilharm A Wilkinson RJ Willimsky G Wing JB Winkelmann R Winkler TH Wirz OF Wong A Wurst P Yang JHM Yang J Yazdanbakhsh M Yu L Yue A Zhang H Zhao Y Ziegler SM Zielinski C Zimmermann J Zychlinsky A Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) Eur J Immunol 2019 49 1457 1973 31633216 10.1002/eji.201970107 PMC7350392

109 Maecker HT Hassler J Payne JK Summers A Comatas K Ghanayem M Morse MA Clay TM Lyerly HK Bhatia S Ghanekar SA Maino VC Delarosa C Disis ML Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides BMC Immunol 2008 9 9 18366814 10.1186/1471-2172-9-9 PMC2275721

110 Balagopal A Barin B Quinn J Rogers R Sulkowski MS Stock PG Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons PLoS One 2015 10 e0135882 26313939 10.1371/journal.pone.0135882 PMC4551738

111 Zhu T He Y Wang Y Zhao L GrimAge and GrimAge2 Age Acceleration effectively predict mortality risk: a retrospective cohort study Epigenetics 2025 20 2530618 40658048 10.1080/15592294.2025.2530618 PMC12269703

112 Kalina T Reproducibility of Flow Cytometry Through Standardization: Opportunities and Challenges Cytometry A 2020 97 137 147 31593368 10.1002/cyto.a.23901

113 Cossarizza A Chang HD Radbruch A Abrignani S Addo R Akdis M Andrä I Andreata F Annunziato F Arranz E Bacher P Bari S Barnaba V Barros-Martins J Baumjohann D Beccaria CG Bernardo D Boardman DA Borger J Böttcher C Brockmann L Burns M Busch DH Cameron G Cammarata I Cassotta A Chang Y Chirdo FG Christakou E Čičin-Šain L Cook L Corbett AJ Cornelis R Cosmi L Davey MS De Biasi S De Simone G Del Zotto G Delacher M Di Rosa F Di Santo J Diefenbach A Dong J Dörner T Dress RJ Dutertre CA Eckle SBG Eede P Evrard M Falk CS Feuerer M Fillatreau S Fiz-Lopez A Follo M Foulds GA Fröbel J Gagliani N Galletti G Gangaev A Garbi N Garrote JA Geginat J Gherardin NA Gibellini L Ginhoux F Godfrey DI Gruarin P Haftmann C Hansmann L Harpur CM Hayday AC Heine G Hernández DC Herrmann M Hoelsken O Huang Q Huber S Huber JE Huehn J Hundemer M Hwang WYK Iannacone M Ivison SM Jäck HM Jani PK Keller B Kessler N Ketelaars S Knop L Knopf J Koay HF Kobow K Kriegsmann K Kristyanto H Krueger A Kuehne JF Kunze-Schumacher H Kvistborg P Kwok I Latorre D Lenz D Levings MK Lino AC Liotta F Long HM Lugli E MacDonald KN Maggi L Maini MK Mair F Manta C Manz RA Mashreghi MF Mazzoni A McCluskey J Mei HE Melchers F Melzer S Mielenz D Monin L Moretta L Multhoff G Muñoz LE Muñoz-Ruiz M Muscate F Natalini A Neumann K Ng LG Niedobitek A Niemz J Almeida LN Notarbartolo S Ostendorf L Pallett LJ Patel AA Percin GI Peruzzi G Pinti M Pockley AG Pracht K Prinz I Pujol-Autonell I Pulvirenti N Quatrini L Quinn KM Radbruch H Rhys H Rodrigo MB Romagnani C Saggau C Sakaguchi S Sallusto F Sanderink L Sandrock I Schauer C Scheffold A Scherer HU Schiemann M Schildberg FA Schober K Schoen J Schuh W Schüler T Schulz AR Schulz S Schulze J Simonetti S Singh J Sitnik KM Stark R Starossom S Stehle C Szelinski F Tan L Tarnok A Tornack J Tree TIM van Beek JJP van de Veen W van Gisbergen K Vasco C Verheyden NA von Borstel A Ward-Hartstonge KA Warnatz K Waskow C Wiedemann A Wilharm A Wing J Wirz O Wittner J Yang JHM Yang J Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) Eur J Immunol 2021 51 2708 3145 34910301 10.1002/eji.202170126 PMC11115438

114 Kelleher P Greathead L Whitby L Brando B UK NEQAS Leucocyte Immunophenotyping Steering Committee, Barnett D, Bloxham D, deTute R, Dunlop A, Farren T, Francis S, Payne D, Scott S, Snowden JA, Sorour Y, Stansfield E, Virgo P, Whitby A European flow cytometry quality assurance guidelines for the diagnosis of primary immune deficiencies and assessment of immune reconstitution following B cell depletion therapies and transplantation Cytometry B Clin Cytom 2024 106 424 436 38940298 10.1002/cyto.b.22195

115 Huang B Liu R Wang P Yuan Z Yang J Xiong H Zhang N Huang Q Fu X Sun W Li L CD8(+)CD57(+) T cells exhibit distinct features in human non-small cell lung cancer J Immunother Cancer 2020 8 e000639 32606053 10.1136/jitc-2020-000639 PMC7328901

116 Garcia-Prat M Álvarez-Sierra D Aguiló-Cucurull A Salgado-Perandrés S Briongos-Sebastian S Franco-Jarava C Martin-Nalda A Colobran R Montserrat I Hernández-González M Pujol-Borrell R Soler-Palacin P Martínez-Gallo M Extended immunophenotyping reference values in a healthy pediatric population Cytometry B Clin Cytom 2019 96 223 233 30334372 10.1002/cyto.b.21728

117 Gutierrez-Rodrigues F Santana-Lemos BA Scheucher PS Alves-Paiva RM Calado RT Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans PLoS One 2014 9 e113747 25409313 10.1371/journal.pone.0113747 PMC4237503

118 Pearce EE Horvath S Katta S Dagnall C Aubert G Hicks BD Spellman SR Katki H Savage SA Alsaggaf R Gadalla SM DNA-methylation-based telomere length estimator: comparisons with measurements from flow FISH and qPCR Aging (Albany NY) 2021 13 14675 14686 34083495 10.18632/aging.203126 PMC8221337

119 McCrory C Fiorito G Hernandez B Polidoro S O'Halloran AM Hever A Ni Cheallaigh C Lu AT Horvath S Vineis P Kenny RA GrimAge Outperforms Other Epigenetic Clocks in the Prediction of Age-Related Clinical Phenotypes and All-Cause Mortality J Gerontol A Biol Sci Med Sci 2021 76 741 749 33211845 10.1093/gerona/glaa286 PMC8087266

120 Harmon W Meyers K Ingelfinger J McDonald R McIntosh M Ho M Spaneas L Palmer JA Hawk M Geehan C Tinckam K Hancock WW Sayegh MH Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation J Am Soc Nephrol 2006 17 1735 1745 16687625 10.1681/ASN.2006010049

121 Liu F Mao JH Calcineurin inhibitors and nephrotoxicity in children World J Pediatr 2018 14 121 126 29532435 10.1007/s12519-018-0125-y

122 Karolin A Genitsch V Sidler D Calcineurin Inhibitor Toxicity in Solid Organ Transplantation Pharmacology 2021 106 347 355 34130291 10.1159/000515933

123 Kirkland JL Tchkonia T Senolytic drugs: from discovery to translation J Intern Med 2020 288 518 536 32686219 10.1111/joim.13141 PMC7405395

124 Zhu Y Tchkonia T Pirtskhalava T Gower AC Ding H Giorgadze N Palmer AK Ikeno Y Hubbard GB Lenburg M O'Hara SP LaRusso NF Miller JD Roos CM Verzosa GC LeBrasseur NK Wren JD Farr JN Khosla S Stout MB McGowan SJ Fuhrmann-Stroissnigg H Gurkar AU Zhao J Colangelo D Dorronsoro A Ling YY Barghouthy AS Navarro DC Sano T Robbins PD Niedernhofer LJ Kirkland JL The Achilles' heel of senescent cells: from transcriptome to senolytic drugs Aging Cell 2015 14 644 658 25754370 10.1111/acel.12344 PMC4531078

125 Xu M Pirtskhalava T Farr JN Weigand BM Palmer AK Weivoda MM Inman CL Ogrodnik MB Hachfeld CM Fraser DG Onken JL Johnson KO Verzosa GC Langhi LGP Weigl M Giorgadze N LeBrasseur NK Miller JD Jurk D Singh RJ Allison DB Ejima K Hubbard GB Ikeno Y Cubro H Garovic VD Hou X Weroha SJ Robbins PD Niedernhofer LJ Khosla S Tchkonia T Kirkland JL Senolytics improve physical function and increase lifespan in old age Nat Med 2018 24 1246 1256 29988130 10.1038/s41591-018-0092-9 PMC6082705

126 Justice JN Nambiar AM Tchkonia T LeBrasseur NK Pascual R Hashmi SK Prata L Masternak MM Kritchevsky SB Musi N Kirkland JL Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study EBioMedicine 2019 40 554 563 30616998 10.1016/j.ebiom.2018.12.052 PMC6412088

127 Yousefzadeh MJ Zhu Y McGowan SJ Angelini L Fuhrmann-Stroissnigg H Xu M Ling YY Melos KI Pirtskhalava T Inman CL McGuckian C Wade EA Kato JI Grassi D Wentworth M Burd CE Arriaga EA Ladiges WL Tchkonia T Kirkland JL Robbins PD Niedernhofer LJ Fisetin is a senotherapeutic that extends health and lifespan EBioMedicine 2018 36 18 28 30279143 10.1016/j.ebiom.2018.09.015 PMC6197652

128 Chang J Wang Y Shao L Laberge RM Demaria M Campisi J Janakiraman K Sharpless NE Ding S Feng W Luo Y Wang X Aykin-Burns N Krager K Ponnappan U Hauer-Jensen M Meng A Zhou D Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice Nat Med 2016 22 78 83 26657143 10.1038/nm.4010 PMC4762215

129 Laberge RM Sun Y Orjalo AV Patil CK Freund A Zhou L Curran SC Davalos AR Wilson-Edell KA Liu S Limbad C Demaria M Li P Hubbard GB Ikeno Y Javors M Desprez PY Benz CC Kapahi P Nelson PS Campisi J MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation Nat Cell Biol 2015 17 1049 1061 26147250 10.1038/ncb3195 PMC4691706

130 Barzilai N Crandall JP Kritchevsky SB Espeland MA Metformin as a Tool to Target Aging Cell Metab 2016 23 1060 1065 27304507 10.1016/j.cmet.2016.05.011 PMC5943638

131 Bannister CA Holden SE Jenkins-Jones S Morgan CL Halcox JP Schernthaner G Mukherjee J Currie CJ Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls Diabetes Obes Metab 2014 16 1165 1173 25041462 10.1111/dom.12354

132 Xu M Tchkonia T Ding H Ogrodnik M Lubbers ER Pirtskhalava T White TA Johnson KO Stout MB Mezera V Giorgadze N Jensen MD LeBrasseur NK Kirkland JL JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age Proc Natl Acad Sci U S A 2015 112 E6301 E6310 26578790 10.1073/pnas.1515386112 PMC4655580

133 Freund A Patil CK Campisi J p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype EMBO J 2011 30 1536 1548 21399611 10.1038/emboj.2011.69 PMC3102277

134 Lelarge V Capelle R Oger F Mathieu T Le Calvé B Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment NPJ Aging 2024 10 12 38321020 10.1038/s41514-024-00138-4 PMC10847408

135 Carpenter VJ Saleh T Gewirtz DA Senolytics for Cancer Therapy: Is All That Glitters Really Gold? Cancers (Basel) 2021 13 723 33578753 10.3390/cancers13040723 PMC7916462

136 Romashkan S Chang H Hadley EC National Institute on Aging Workshop: Repurposing Drugs or Dietary Supplements for Their Senolytic or Senomorphic Effects: Considerations for Clinical Trials J Gerontol A Biol Sci Med Sci 2021 76 1144 1152 33528569 10.1093/gerona/glab028 PMC8521777

137 Chaib S Tchkonia T Kirkland JL Cellular senescence and senolytics: the path to the clinic Nat Med 2022 28 1556 1568 35953721 10.1038/s41591-022-01923-y PMC9599677

138 Debrincat MA Pleines I Lebois M Lane RM Holmes ML Corbin J Vandenberg CJ Alexander WS Ng AP Strasser A Bouillet P Sola-Visner M Kile BT Josefsson EC BCL-2 is dispensable for thrombopoiesis and platelet survival Cell Death Dis 2015 6 e1721 25880088 10.1038/cddis.2015.97 PMC4650559

139 Ludwig LM Nassin ML Hadji A LaBelle JL Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation Front Pediatr 2016 4 135 28066751 10.3389/fped.2016.00135 PMC5174130

140 Kirkland JL Tchkonia T Zhu Y Niedernhofer LJ Robbins PD The Clinical Potential of Senolytic Drugs J Am Geriatr Soc 2017 65 2297 2301 28869295 10.1111/jgs.14969 PMC5641223

141 Sportès C Hakim FT Memon SA Zhang H Chua KS Brown MR Fleisher TA Krumlauf MC Babb RR Chow CK Fry TJ Engels J Buffet R Morre M Amato RJ Venzon DJ Korngold R Pecora A Gress RE Mackall CL Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets J Exp Med 2008 205 1701 1714 18573906 10.1084/jem.20071681 PMC2442646

142 Mackall CL Fry TJ Gress RE Harnessing the biology of IL-7 for therapeutic application Nat Rev Immunol 2011 11 330 342 21508983 10.1038/nri2970 PMC7351348

143 Napolitano LA Schmidt D Gotway MB Ameli N Filbert EL Ng MM Clor JL Epling L Sinclair E Baum PD Li K Killian ML Bacchetti P McCune JM Growth hormone enhances thymic function in HIV-1-infected adults J Clin Invest 2008 118 1085 1098 18292808 10.1172/JCI32830 PMC2248326

144 Rossi SW Jeker LT Ueno T Kuse S Keller MP Zuklys S Gudkov AV Takahama Y Krenger W Blazar BR Holländer GA Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells Blood 2007 109 3803 3811 17213286 10.1182/blood-2006-10-049767 PMC1874572

145 Markert ML Devlin BH Alexieff MJ Li J McCarthy EA Gupton SE Chinn IK Hale LP Kepler TB He M Sarzotti M Skinner MA Rice HE Hoehner JC Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants Blood 2007 109 4539 4547 17284531 10.1182/blood-2006-10-048652 PMC1885498

146 Parent AV Russ HA Khan IS LaFlam TN Metzger TC Anderson MS Hebrok M Generation of functional thymic epithelium from human embryonic stem cells that supports host T cell development Cell Stem Cell 2013 13 219 229 23684540 10.1016/j.stem.2013.04.004 PMC3869399

147 Bredenkamp N Ulyanchenko S O'Neill KE Manley NR Vaidya HJ Blackburn CC An organized and functional thymus generated from FOXN1-reprogrammed fibroblasts Nat Cell Biol 2014 16 902 908 25150981 10.1038/ncb3023 PMC4153409

148 Yanir A Schulz A Lawitschka A Nierkens S Eyrich M Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to Targeted Interventions Front Pediatr 2021 9 786017 35087775 10.3389/fped.2021.786017 PMC8789272

149 Teshima T Boelens JJ Matsuoka KI Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation Blood Cell Ther 2023 6 42 48 37342354 10.31547/bct-2022-023 PMC10279491

150 Courivaud C Bamoulid J Crepin T Gaiffe E Laheurte C Saas P Ducloux D Pre-transplant Thymic Function Predicts Is Associated With Patient Death After Kidney Transplantation Front Immunol 2020 11 1653 32903778 10.3389/fimmu.2020.01653 PMC7438875

151 Ferrara JL Levine JE Reddy P Holler E Graft-versus-host disease Lancet 2009 373 1550 1561 19282026 10.1016/S0140-6736(09)60237-3 PMC2735047

152 Junnila RK List EO Berryman DE Murrey JW Kopchick JJ The GH/IGF-1 axis in ageing and longevity Nat Rev Endocrinol 2013 9 366 376 23591370 10.1038/nrendo.2013.67 PMC4074016

153 Chhabra Y Waters MJ Brooks AJ Role of the growth hormone-IGF-1 axis in cancer Expert Rev Endocrinol Metab 2011 6 71 84 30764037 10.1586/eem.10.73

154 Rajman L Chwalek K Sinclair DA Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence Cell Metab 2018 27 529 547 29514064 10.1016/j.cmet.2018.02.011 PMC6342515

155 Martens CR Denman BA Mazzo MR Armstrong ML Reisdorph N McQueen MB Chonchol M Seals DR Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults Nat Commun 2018 9 1286 29599478 10.1038/s41467-018-03421-7 PMC5876407

156 Cantó C Auwerx J NAD+ as a signaling molecule modulating metabolism Cold Spring Harb Symp Quant Biol 2011 76 291 298 22345172 10.1101/sqb.2012.76.010439 PMC3616234

157 Filler G Feber J The transplanted child: New immunosuppressive agents and the need for pharmacokinetic monitoring Paediatr Child Health 2002 7 525 532 20046464 10.1093/pch/7.8.525 PMC2797482

158 Al Riyami MS Al Gaithi B Al Kalbani N Al Saidi S Immunosuppressive Therapy in Pediatric Kidney Transplantation: Evolution, Current Practices, and Future Directions Biomedicines 2025 13 3084 41463094 10.3390/biomedicines13123084 PMC12730651

159 Damgaard MV Treebak JT What is really known about the effects of nicotinamide riboside supplementation in humans Sci Adv 2023 9 eadi4862 37478182 10.1126/sciadv.adi4862 PMC10361580

160 Freeberg KA Udovich CC Martens CR Seals DR Craighead DH Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions J Gerontol A Biol Sci Med Sci 2023 78 2435 2448 37068054 10.1093/gerona/glad106 PMC10692436

161 Gerner RR Macheiner S Reider S Siegmund K Grabherr F Mayr L Texler B Moser P Effenberger M Schwaighofer H Moschen AR Kircher B Oberacher H Zeiser R Tilg H Nachbaur D Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity Leukemia 2020 34 1885 1897 31974433 10.1038/s41375-020-0709-0

162 Chancharoenthana W Traitanon O Leelahavanichkul A Tasanarong A Molecular immune monitoring in kidney transplant rejection: a state-of-the-art review Front Immunol 2023 14 1206929 37675106 10.3389/fimmu.2023.1206929 PMC10477600

163 Murphy MP Smith RA Targeting antioxidants to mitochondria by conjugation to lipophilic cations Annu Rev Pharmacol Toxicol 2007 47 629 656 17014364 10.1146/annurev.pharmtox.47.120505.105110

164 Skulachev VP Anisimov VN Antonenko YN Bakeeva LE Chernyak BV Erichev VP Filenko OF Kalinina NI Kapelko VI Kolosova NG Kopnin BP Korshunova GA Lichinitser MR Obukhova LA Pasyukova EG Pisarenko OI Roginsky VA Ruuge EK Senin II Severina II Skulachev MV Spivak IM Tashlitsky VN Tkachuk VA Vyssokikh MY Yaguzhinsky LS Zorov DB An attempt to prevent senescence: a mitochondrial approach Biochim Biophys Acta 2009 1787 437 461 19159610 10.1016/j.bbabio.2008.12.008

165 Gioscia-Ryan RA LaRocca TJ Sindler AL Zigler MC Murphy MP Seals DR Mitochondria-targeted antioxidant (MitoQ) ameliorates age-related arterial endothelial dysfunction in mice J Physiol 2014 592 2549 2561 24665093 10.1113/jphysiol.2013.268680 PMC4080937

166 Fontana L Partridge L Longo VD Extending healthy life span--from yeast to humans Science 2010 328 321 326 20395504 10.1126/science.1172539 PMC3607354

167 Longo VD Mattson MP Fasting: molecular mechanisms and clinical applications Cell Metab 2014 19 181 192 24440038 10.1016/j.cmet.2013.12.008 PMC3946160

168 Sharma P Allison JP The future of immune checkpoint therapy Science 2015 348 56 61 25838373 10.1126/science.aaa8172

169 Lipson EJ Bodell MA Kraus ES Sharfman WH Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma J Clin Oncol 2014 32 e69 e71 24493726 10.1200/JCO.2013.49.2314 PMC4870592

170 Kumar V Shinagare AB Rennke HG Ghai S Lorch JH Ott PA Rahma OE The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature Oncologist 2020 25 505 514 32043699 10.1634/theoncologist.2019-0659 PMC7288631

171 Gassmann D Weiler S Mertens JC Reiner CS Vrugt B Nägeli M Mangana J Müllhaupt B Jenni F Misselwitz B Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research Transplant Direct 2018 4 e376 30255136 10.1097/TXD.0000000000000814 PMC6092180

172 Kayali S Pasta A Plaz Torres MC Jaffe A Strazzabosco M Marenco S Giannini EG Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis Liver Int 2023 43 8 17 36102312 10.1111/liv.15419 PMC10087158

173 Anugwom CM Leventhal TM Debes JD Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant Hepatoma Res 2022 8 7 35693455 10.20517/2394-5079.2021.123 PMC9181209

174 Aguirre LE Guzman ME Lopes G Hurley J Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue Oncologist 2019 24 394 401 30413665 10.1634/theoncologist.2018-0195 PMC6519766

175 Morrison SA Vinson AJ Acute Allograft Rejection in Kidney Transplant Recipients Treated With Immune Checkpoint Inhibitors: An Educational Case Report Can J Kidney Health Dis 2024 11 20543581241289191 39444717 10.1177/20543581241289191 PMC11497508

176 Robinson CH Coughlin CC Chanchlani R Dharnidharka VR Post-transplant malignancies in pediatric organ transplant recipients Pediatr Transplant 2021 25 e13884 33111463 10.1111/petr.13884

177 Bolufer M Soler J Molina M Taco O Vila A Macía M Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits Transpl Int 2024 37 13204 39654653 10.3389/ti.2024.13204 PMC11625584

178 Liu X Lu Y Zhou W Peng T Zhou J Bi H Xia F Chen X Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition) Liver Cancer 2024 13 355 375 39114757 10.1159/000535496 PMC11305662

179 Carroll RP Boyer M Gebski V Hockley B Johnston JK Kireta S Tan H Taylor A Wyburn K Zalcberg JR Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study Lancet Oncol 2022 23 1078 1086 35809595 10.1016/S1470-2045(22)00368-0

180 Kawashima S Joachim K Abdelrahim M Abudayyeh A Jhaveri KD Murakami N Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates Korean J Transplant 2022 36 82 98 35919193 10.4285/kjt.22.0013 PMC9296977

181 June CH O'Connor RS Kawalekar OU Ghassemi S Milone MC CAR T cell immunotherapy for human cancer Science 2018 359 1361 1365 29567707 10.1126/science.aar6711

182 Ligon JA Wessel KM Shah NN Glod J Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions Front Immunol 2022 13 846346 35273619 10.3389/fimmu.2022.846346 PMC8901720

183 Ghoneim HE Fan Y Moustaki A Abdelsamed HA Dash P Dogra P Carter R Awad W Neale G Thomas PG Youngblood B De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation Cell 2017 170 142 157.e19 28648661 10.1016/j.cell.2017.06.007 PMC5568784

184 Bengsch B Johnson AL Kurachi M Odorizzi PM Pauken KE Attanasio J Stelekati E McLane LM Paley MA Delgoffe GM Wherry EJ Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion Immunity 2016 45 358 373 27496729 10.1016/j.immuni.2016.07.008 PMC4988919

185 Razonable RR Humar A Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice Clin Transplant 2019 33 e13512 30817026 10.1111/ctr.13512

186 Tzannou I Papadopoulou A Naik S Leung K Martinez CA Ramos CA Carrum G Sasa G Lulla P Watanabe A Kuvalekar M Gee AP Wu MF Liu H Grilley BJ Krance RA Gottschalk S Brenner MK Rooney CM Heslop HE Leen AM Omer B Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation J Clin Oncol 2017 35 3547 3557 28783452 10.1200/JCO.2017.73.0655 PMC5662844

187 Pass RF Zhang C Evans A Simpson T Andrews W Huang ML Corey L Hill J Davis E Flanigan C Cloud G Vaccine prevention of maternal cytomegalovirus infection N Engl J Med 2009 360 1191 1199 19297572 10.1056/NEJMoa0804749 PMC2753425

188 Sperotto A Candoni A Gottardi M Facchin G Stella R De Marchi R Michelutti A Cavallin M Rosignoli C Patriarca F Fanin R Cytomegalovirus Prophylaxis versus Pre-emptive Strategy: Different CD4(+) and CD8(+) T Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation Transplant Cell Ther 2021 27 518.e1 518.e4 10.1016/j.jtct.2021.03.003 33812803

189 Legendre C Pascual M Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences Clin Infect Dis 2008 46 732 740 18220478 10.1086/527397

190 Foca M Demirhan S Munoz FM Valencia Deray KG Bocchini CE Sharma TS Sherman G Muller WJ Heald-Sargent T Danziger-Isakov L Blum S Boguniewicz J Bacon S Joseph T Smith J Ardura MI Su Y Maron GM Ferrolino J Herold BC Multicenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients Open Forum Infect Dis 2024 11 ofae353 38979014 10.1093/ofid/ofae353 PMC11229698

191 Kotton CN CMV: Prevention, Diagnosis and Therapy Am J Transplant 2013 13 Suppl 3 24 40; quiz 40 23347212 10.1111/ajt.12006

192 Otto WR Green A Antiviral Therapeutics in Pediatric Transplant Recipients Infect Dis Clin North Am 2022 36 125 146 35168706 10.1016/j.idc.2021.11.004 PMC8900721

193 Hoegy D Bleyzac N Robinson P Bertrand Y Dussart C Janoly-Dumenil A Medication adherence in pediatric transplantation and assessment methods: a systematic review Patient Prefer Adherence 2019 13 705 719 31123396 10.2147/PPA.S200209 PMC6511245

194 Jenkins FJ Rowe DT Rinaldo CR Jr Herpesvirus infections in organ transplant recipients Clin Diagn Lab Immunol 2003 10 1 7 12522031 10.1128/CDLI.10.1.1-7.2003 PMC145294

195 Sen P Wilkie AR Ji F Yang Y Taylor IJ Velazquez-Palafox M Vanni EAH Pesola JM Fernandez R Chen H Morsett LM Abels ER Piper M Lane RJ Hickman SE Means TK Rosenberg ES Sadreyev RI Li B Coen DM Fishman JA El Khoury J Linking indirect effects of cytomegalovirus in transplantation to modulation of monocyte innate immune function Sci Adv 2020 6 eaax9856 32494628 10.1126/sciadv.aax9856 PMC7176434

196 Vaiserman AM Koliada AK Marotta F Gut microbiota: A player in aging and a target for anti-aging intervention Ageing Res Rev 2017 35 36 45 28109835 10.1016/j.arr.2017.01.001

197 Lee JR Muthukumar T Dadhania D Taur Y Jenq RR Toussaint NC Ling L Pamer E Suthanthiran M Gut microbiota and tacrolimus dosing in kidney transplantation PLoS One 2015 10 e0122399 25815766 10.1371/journal.pone.0122399 PMC4376942

198 Hill C Guarner F Reid G Gibson GR Merenstein DJ Pot B Morelli L Canani RB Flint HJ Salminen S Calder PC Sanders ME Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic Nat Rev Gastroenterol Hepatol 2014 11 506 514 24912386 10.1038/nrgastro.2014.66

199 Cammarota G Ianiro G Tilg H Rajilić-Stojanović M Kump P Satokari R Sokol H Arkkila P Pintus C Hart A Segal J Aloi M Masucci L Molinaro A Scaldaferri F Gasbarrini G Lopez-Sanroman A Link A de Groot P de Vos WM Högenauer C Malfertheiner P Mattila E Milosavljević T Nieuwdorp M Sanguinetti M Simren M Gasbarrini A European FMT Working Group European consensus conference on faecal microbiota transplantation in clinical practice Gut 2017 66 569 580 28087657 10.1136/gutjnl-2016-313017 PMC5529972

200 De Filippis F Pellegrini N Vannini L Jeffery IB La Storia A Laghi L Serrazanetti DI Di Cagno R Ferrocino I Lazzi C Turroni S Cocolin L Brigidi P Neviani E Gobbetti M O'Toole PW Ercolini D High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome Gut 2016 65 1812 1821 26416813 10.1136/gutjnl-2015-309957

201 Ebrahim NAA Farghaly TA Soliman SMA "Exosomal blueprint of lung-tropic metastasis: molecular signatures, microenvironmental conditioning, and translational implications in cancer" Med Oncol 2025 43 93 41452573 10.1007/s12032-025-03217-y

202 Andermann TM Rezvani A Bhatt AS Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation Curr Hematol Malig Rep 2016 11 19 28 26780719 10.1007/s11899-016-0302-9 PMC4996265

203 Ebrahim NAA Farghaly TA Soliman SMA Rewiring the transcriptome: diagnostic and therapeutic implications of alternative splicing in solid cancers Mol Biol Rep 2025 53 125 41296088 10.1007/s11033-025-11302-8

204 Liu Y Wang J Wu C Modulation of Gut Microbiota and Immune System by Probiotics, Pre-biotics, and Post-biotics Front Nutr 2021 8 634897 35047537 10.3389/fnut.2021.634897 PMC8761849

205 Ebrahim NAA Farghaly TA Soliman SMA 4D-printed microdevices for spatiotemporal detection of ctDNA and miRNA in pancreatic cancer: an in-depth review Med Oncol 2025 42 462 40903656 10.1007/s12032-025-03021-8